Investigations on the role of GILZ in statin therapy and the influence of glucocorticoid metabolism in age-related inflammation by Valbuena Perez, Jenny Vanessa
  
 
 
Investigations on the role of GILZ in statin therapy 
and the influence of glucocorticoid metabolism in 
age-related inflammation 
 
 
 
 
 
 
Dissertation 
zur Erlangung des Grades 
des Doktors der Naturwissenschaften 
der Naturwissenschaftlich-Technischen Fakultät 
der Universität des Saarlandes 
 
 
 
 
von 
Jenny Vanessa Valbuena Pérez 
 
 
 
Saarbrücken 
2019 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tag des Kolloquiums: 16.07.2019 
Dekan: Univ.-Prof. Dr. rer. nat. Guido Kickelbick 
Berichterstatter: Prof. Dr. Alexandra K. Kiemer 
          Prof. Dr. Thorsten Lehr 
 
Vorsitz: Prof. Dr. Claus Jacob 
Akad. Mitarbeiter: Dr. Jennifer Herrmann 
 
  
 
 
 
 
 
To the memory of my Abuelita  
I love you, my angel 
 
  
Contents 
 
Abbreviations and Symbols ................................................................................................................... i 
List of Figures ........................................................................................................................................ v 
List of Tables ........................................................................................................................................ vii 
Abstract .................................................................................................................................................. 1 
Zusammenfassung ................................................................................................................................. 2 
1. Introduction ...................................................................................................................................... 3 
1.1 Cardiovascular disease ...................................................................................................... 4 
1.2 Statins .............................................................................................................................. 4 
1.2.1 Pharmacological and pharmacokinetic aspects .................................................................. 4 
1.2.2 Pleiotropic effects of statins ............................................................................................. 6 
1.2.3 Statin-associated muscle symptoms .................................................................................. 6 
1.3 The glucocorticoid-induced leucine zipper (GILZ) .............................................................. 7 
1.4 Aging and age-related diseases ........................................................................................... 8 
1.4.1 Inflammaging ................................................................................................................. 9 
1.5 Glucocorticoid function and metabolism ............................................................................. 9 
1.5.1 Regulation of glucocorticoid response and function .......................................................... 9 
1.5.2 Glucocorticoids in inflammation .................................................................................... 10 
1.6 Aim of the present work .................................................................................................. 12 
2. Materials and Methods .................................................................................................................. 13 
2.1 Chemicals and reagents ................................................................................................... 14 
2.1.1 General Buffers ............................................................................................................ 14 
2.2 Cell culture ..................................................................................................................... 15 
2.2.1 Cell lines ...................................................................................................................... 15 
2.2.2 Cell freezing / thawing .................................................................................................. 15 
2.2.3 Primary cells ................................................................................................................ 15 
2.3 Bacterial culture .............................................................................................................. 17 
2.3.1 Generation of competent E. Coli .................................................................................... 18 
2.3.2 Plasmid isolation .......................................................................................................... 18 
  
2.4 Mice ............................................................................................................................... 18 
2.5 RNA isolation and reverse transcription ............................................................................ 18 
2.6 Quantitative Polymerase Chain Reaction (qPCR) .............................................................. 19 
2.7 Western blot ................................................................................................................... 21 
2.7.1 Near-Infrared detection ................................................................................................. 22 
2.7.2 Chemiluminescent detection .......................................................................................... 22 
2.8 Cytotoxicity measurement ............................................................................................... 23 
2.9 Effects of statins on C2C12 differentiation ........................................................................ 23 
2.10 Jenner-Giemsa staining .................................................................................................... 24 
2.11 Immunofluorescence ....................................................................................................... 24 
2.11.1 Whole-zebrafish immunofluorescence ............................................................................ 25 
2.12 GILZ induction under statin treatment .............................................................................. 25 
2.13 Gene expression in zebrafish embryos under statin treatment ............................................. 26 
2.14 Chromatin immunoprecipitation (ChIP) ............................................................................ 26 
2.15 Lentiviral transductions and stable cell line generation ...................................................... 27 
2.15.1 Lentivirus generation .................................................................................................... 27 
2.15.2 Lentiviral titre .............................................................................................................. 27 
2.15.3 Antibiotic kill curve ...................................................................................................... 28 
2.15.4 Generation of C2C12shGILZ stable cell lines ................................................................. 29 
2.15.5 KLF2 overexpression .................................................................................................... 29 
2.15.6 Generation of RAW 264.7Cas9 cells ................................................................................ 29 
2.16 Short interfering (si) RNA-mediated gene knockdown ....................................................... 30 
2.17 Morpholino-mediated Gilz silencing and mRNA-mediated overexpression in zebrafish ....... 30 
2.17.1 Morpholino (MO) design and mRNA synthesis .............................................................. 30 
2.17.2 MO and mRNA Injection .............................................................................................. 30 
2.18 CRISPR/Cas9-mediated GILZ knockout ........................................................................... 31 
2.18.1 Verification of editing efficiency ................................................................................... 31 
2.18.2 Sequencing analysis ...................................................................................................... 31 
2.19 Serum Analysis ............................................................................................................... 32 
2.20 Thiobarbituric acid reactive substances (TBARS) assay ..................................................... 32 
  
2.21 Determination of 11β-HSD1 activity in peritoneal macrophages ......................................... 32 
2.22 Determination of steroid levels via LC-HRMS/MS ............................................................ 32 
2.23 Statistics ......................................................................................................................... 33 
3. Chapter I ......................................................................................................................................... 34 
3.1 Introduction .................................................................................................................... 35 
3.2 Results ........................................................................................................................... 37 
3.2.1 Statins are toxic towards skeletal muscle cells ................................................................ 37 
3.2.2 Non-toxic concentrations of statin induce GILZ in skeletal muscle cells ........................... 37 
3.2.3 Toxic concentrations of statin induce GILZ expression ................................................... 38 
3.2.4 GILZ induction can be reversed by geranylgeranyl pyrophosphate ................................... 38 
3.2.5 Statin-induced impairment of myogenesis is accompanied by GILZ induction .................. 39 
3.2.6 GILZ knockout abolishes the cytotoxic effects of statins ................................................. 41 
3.2.7 GILZ contributes to statin-induced inhibition of myogenesis ........................................... 44 
3.2.8 FoxO3 mediates GILZ induction by statins in muscle ...................................................... 48 
3.2.9 Statins induce Gilz in zebrafish embryos, and deregulation of Gilz expression impairs 
somitogenesis ........................................................................................................................ 48 
3.3 Discussion ...................................................................................................................... 51 
4. Chapter II ....................................................................................................................................... 55 
4.1 Introduction .................................................................................................................... 56 
4.2 Results ........................................................................................................................... 57 
4.2.1 Statin cytotoxicity towards endothelial cells and macrophages ......................................... 57 
4.2.2 Atorvastatin induces GILZ expression in endothelial cells and macrophages .................... 57 
4.2.3 Statin-induced GILZ expression in HUVECs is mevalonate-dependent ............................ 59 
4.2.4 KLF2 is not involved in the regulation of GILZ expression in endothelial cells ................. 59 
4.2.5 Development of a GILZ-KO endothelial cell line model via CRISPR/Cas9 editing ........... 60 
4.3 Discussion ...................................................................................................................... 64 
5. Chapter III ...................................................................................................................................... 66 
5.1 Introduction .................................................................................................................... 67 
5.2 Results ........................................................................................................................... 69 
5.2.1 Lipid peroxidation and clinical chemistry analysis .......................................................... 69 
5.2.2 Cytokine expression in tissues from aged mice ............................................................... 70 
  
5.2.3 Altered glucocorticoid homeostasis in myeloid cells from aged mice................................ 70 
5.2.4 Reduced corticosterone levels and 11β-HSD1 activity in aged mice ................................. 74 
5.2.5 Upstream regulators of 11β-HSD1 are downregulated in aged macrophages ..................... 74 
5.3 Discussion ...................................................................................................................... 76 
6. Summary and Conclusions ............................................................................................................ 79 
7. References ....................................................................................................................................... 82 
Appendix .............................................................................................................................................. 95 
Appendix 1 .............................................................................................................................. 96 
Appendix 2 .............................................................................................................................. 98 
Appendix 3 ............................................................................................................................ 100 
Acknowledgments .............................................................................................................................. 101 
 
Abbreviations 
 
i 
 
Abbreviations and Symbols 
11-DHC 11-dehydrocorticosterone 
aa amino acids 
ACTH adrenocorticotropic hormone 
Akt RAC-alpha serine/threonine-protein kinase 
ALT alanine transaminase 
ANOVA analysis of variance 
AP-1 activator protein 1 
AST aspartate transaminase 
ATCC American Type Culture Collection 
AVP arginine vasopressin 
BCA bicinchoninic acid 
BMM bone marrow-derived macrophages 
bp base pairs 
BSA bovine serum albumin 
Ca(NO3)2 calcium nitrate 
CaCl2 calcium chloride 
Cas9 CRISPR associated protein 9 
CBG corticosteroid-binding globulin 
cDNA complementary DNA 
ChIP chromatin immunoprecipitation 
CI confidence interval 
CRH corticotropin-releasing hormone 
CRISPR clustered regularly interspaced short palindromic repeats 
CRP C-reactive protein 
CVD cardiovascular disease 
DAPI 4′,6-diamidino-2-phenylindole 
DHEA dehydroepiandrosterone 
DM differentiation medium 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DPBS Dulbecco's Phosphate-Buffered Saline 
ECACC European Collection of Authenticated Cell Cultures 
ECGM endothelial cell growth medium 
ECL enhanced chemiluminescence 
Abbreviations 
 
ii 
 
EDTA ethylene diamine tetracetic acid 
ELISA enzyme-linked immunosorbent assay 
FBS foetal bovine serum 
FDB flexor digitorum brevis 
FHRE forkhead response element 
FoxO3a forkhead box O3 
FPP farnesyl pyrophosphate 
GADPH glyceraldehyde 3-phosphate dehydrogenase 
GC glucocorticoid 
gDNA genomic DNA 
GGPP geranylgeranyl pyrophosphate 
GILZ glucocorticoid-induced leucine zipper 
GM growth medium 
GR glucocorticoid receptor 
GRE glucocorticoid response element 
GTP guanosine triphosphate 
H3BO3 boric acid 
HCl hydrochloric acid 
HEPES hydroxyethyl piperazineethanesulfonic acid 
HESI heated electrospray ionization 
HIV human immunodeficiency virus 
HMG-CoA 3-hydroxy-3-methylglutaryl coenzyme A 
HPA hypothalamic-pituitary-adrenal 
hpf hours post-fertilization 
HRP horseradish peroxidase 
HSD hydroxysteroid dehydrogenase 
HUVEC human umbilical endothelial vein cells 
ICE inference of CRISPR Edits 
IF immunofluorescence 
IGF-1 insulin-like growth factor-1 
IgG immunoglobulin G 
IL interleukin 
IQR interquartile range 
IRE insulin response element 
KCl potassium chloride 
KH2PO4 potassium dihydrogen phosphate 
KHCO3 potassium bicarbonate 
KLF2 Krüppel-like factor 2 
KD knockdown 
Abbreviations 
 
iii 
 
KO knockout 
LB lysogeny broth 
LC-HRMS/MS liquid chromatography-high resolution mass spectrometry 
LDL-C low-density lipoprotein cholesterol 
LPS lipopolysaccharide 
mAb monoclonal antibody 
Mcl-1 induced myeloid leukaemia cell differentiation protein 
M-CSF macrophage colony-stimulating factor 
MDA malondialdehyde 
MgSO4 magnesium sulphate 
MHC major histocompatibility complex 
MHC myosin heavy chain 
MMP matrix metalloproteinase 
MO morpholino 
MOI multiplicity of infection 
MRF myogenic regulatory factor 
mRNA messenger RNA 
mTOR mammalian target of rapamycin 
MTT 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide 
MVA mevalonic acid 
Na2HPO4 sodium hydrogen phosphate 
NaCl sodium chloride 
NADH nicotinamide adenine dinucleotide 
NADPH nicotinamide adenine dinucleotide phosphate 
NaH2PO4 sodium dihydrogen phosphate 
NCE normalised collision energy 
NF-κB nuclear factor kappa B 
NH4Cl ammonium chloride 
NHEJ non-homologous end joining 
NO nitric oxide 
NOS nitric oxide synthase 
PBL peripheral blood leukocytes 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PER proline/glutamate-rich 
PGC-1α peroxisome-proliferator-activated receptor coactivator-1α 
PI3K phosphoinositide 3 kinase 
PM peritoneal macrophages 
Abbreviations 
 
iv 
 
PRR pattern recognition receptors 
PVDF polyvinylidene difluoride 
RBB Rockland blocking buffer 
RIPA radio Immunoprecipitation Assay 
RNA ribonucleic acid 
RNase ribonuclease 
ROS reactive oxygen species 
RT-qPCR reverse transcription – quantitative PCR 
SAMS statin-associated muscle symptoms 
SDS sodium dodecyl sulphate 
SDS-PAGE SDS-polyacrylamide gel electrophoresis 
SEM standard error of the mean 
sgRNA single guide RNA 
shRNA short hairpin RNA 
SINE short interspersed elements 
siRNA small interfering RNA 
TBARS thiobarbituric acid reactive substances 
TBE Tris/Borate/EDTA 
TGF-β transforming growth factor β 
TNF-α tumour necrosis factor α 
tSIM targeted single ion monitoring 
TU transducing units 
UA uric acid 
UHPLC ultra-high-performance liquid chromatography 
VP viral particles 
WT wildtype 
List of Figures 
 
v 
 
List of Figures 
Figure 1.1. General aspects of statins. 5 
Figure 1.2. GILZ structure and functional domains. 7 
Figure 1.3. The seven pillars of aging.  8 
Figure 1.4. Regulation of cortisol levels. 10 
Figure 3.1. Analysis of the publicly available ArrayExpress dataset E-TABM-116: 36 
Figure 3.2. Statin cytotoxicity towards muscle cells. 37 
Figure 3.3. Effect of statin treatment on Gilz mRNA expression in C2C12. 38 
Figure 3.4. Effect of statin treatment at toxic concentrations on GILZ expression in 
muscle cells. 
39 
Figure 3.5. Effect of statins on C2C12 differentiation. 40 
Figure 3.6. Effect of statins on GILZ expression during myogenesis. 41 
Figure 3.7. Effect of GILZ knockout on statin-induced myotoxicity. 42 
Figure 3.8. Effect of GILZ knockout on statin-induced FDB myofibre toxicity. 43 
Figure 3.9. Effect of GILZ knockout on statin-induced anti-myogenic effects 44 
Figure 3.10. Gilz expression in stable C2C12shGilz cell lines. 45 
Figure 3.11. Effect of GILZ absence on statin-induced anti-myogenic effects, as 
measured by MHC IF. 
46 
Figure 3.12. Effect of GILZ absence on statin-induced anti-myogenic effects, as 
measured by Jenner-Giemsa staining. 
47 
Figure 3.13. Involvement of FoxO3 in statin-induced GILZ expression. 49 
Figure 3.14. Effect of statins on gene expression in zebrafish, and effect of gilz 
deregulation in zebrafish muscle development. 
50 
Figure 4.1. Statin cytotoxicity towards endothelial cells. 57 
Figure 4.2. Effect of statin treatment on mRNA expression in endothelial cells and 
macrophages. 
58 
Figure 4.3. Effect of mevalonate on statin-induced GILZ expression in endothelial 
cells. 
59 
Figure 4.4. Effect of KLF2 knockdown and overexpression on GILZ expression in 
endothelial cells. 
60 
Figure 4.5. Effect of statin treatment on GILZ expression in an endothelial cell line. 61 
Figure 4.6. CRISPR/Cas9 – mediated GILZ knockout in cell lines. 62 
Figure 4.7. Validation of CRISPR/Cas9-mediated genome editing in HMEC-1 and 
C2C12 clones via Sanger sequencing. 
63 
Figure 5.1. Aged mice show a pro-inflammatory phenotype. 68 
Figure 5.2. Oxidative stress levels in livers from young and aged mice. 69 
List of Figures 
 
vi 
 
Figure 5.3. Expression of pro-inflammatory cytokines in tissues from young and 
aged mice. 
71 
Figure 5.4. Expression of GC-responsive genes in PM/PBL from young and aged 
mice. 
72 
Figure 5.5. Alterations in glucocorticoid metabolism in aged mice. 73 
Figure 5.6. Differences in serum glucocorticoids and 11β-HSD1 activity in young 
and aged mice. 
74 
Figure 5.7. Gene expression of upstream regulators of 11β-HSD1. 75 
List of Tables 
 
vii 
 
List of Tables 
Table 2.1. Primer sequences and annealing conditions for the transcripts evaluated 
in this study 
20 
Table 2.2. Antibodies used in this study for western blot 22 
Table 2.3. Primers used in the ChIP assay 26 
Table 5.1. Clinical chemistry analysis in serum from young and aged C57BL/6 mice. 69 
 
Abstract 
 
1 
 
Abstract 
The glucocorticoid-induced leucine zipper (GILZ) is an immunomodulatory, ubiquitously 
expressed protein, with multiple roles in different pathophysiological processes. Aim of the 
present study was to evaluate the role of GILZ and glucocorticoid (GC) metabolism in two 
different settings: 
Statins, the most prescribed class of drugs for prevention of cardiovascular disease, exert 
beneficial lipid-lowering independent effects, as well as muscle-related adverse effects, by 
mechanisms not fully understood. The role of GILZ in these mechanisms was investigated. 
Statins were able to induce GILZ expression in skeletal muscle, endothelial cells, and 
macrophages. Moreover, using in vitro, ex vivo and in vivo approaches, we demonstrated that 
GILZ is an important mediator of statin-induced muscle damage. 
The second part of this study focused on aging, which is characterised by a chronic, low-grade 
inflammatory state —termed “inflammaging”— that contributes to age-related pathogenesis. 
The elucidation of the mechanisms that modulate this state is of interest to geroscience. 
Evaluation of the age-associated changes in the myeloid compartment of mice, focusing on 
glucocorticoid metabolism, showed reduced levels of circulating GCs that, together with 
perturbations in GC pre-receptor metabolism in aged macrophages, result in dysregulation of 
the anti-inflammatory networks in these innate immune cells and, thus, might promote the 
inflammaging phenotype.
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Zusammenfassung 
Der Glukokortikoid-induzierte Leucin Zipper (GILZ) stellt ein ubiquitär exprimiertes Protein 
dar und spielt eine Rolle in verschiedenen pathophysiologischen Prozessen. Ziel der 
vorliegenden Studie war es, die Beteiligung von GILZ und des Glukokortikoid (GC)-
Metabolismus in zwei Ansätzen zu untersuchen.  
In der Prävention kardiovaskulärer Erkrankungen stellen Statine die meistverordnete 
Substanzklasse dar. Neben ihrer Lipid-senkenden Wirkung zeichnen sie pleiotrope Effekte 
sowie muskelschädigende Nebenwirkungen aus. Zunächst wurde die Hypothese überprüft, dass 
GILZ für die Vermittlung dieser Prozesse eine Rolle spielt, die nicht in direktem 
Zusammenhang mit der Lipid-Senkung stehen. Statine führten zu einer Erhöhung der GILZ-
Expression in Muskelzellen, Endothelzellen und Makrophagen. Darüber hinaus konnte gezeigt 
werden, dass GILZ als wichtiger Mediator in der Statin-induzierten Muskelschädigung agiert. 
Der zweite Teil der Studie fokussierte auf Alterungsprozesse, die sich durch eine chronische, 
Entzündung auszeichnen. Die Untersuchung alterungsbedingter Änderungen im myeloiden 
Kompartiment von Mäusen zeigte im Hinblick auf deren GC Metabolismus reduzierte Spiegel 
zirkulierender GCs. Zusammen mit Störungen im GC Prä-Rezeptor Metabolismus, wie er in 
alten Mäusen zu finden ist, führt dies zu einer Dysregulation des anti-inflammatorischen 
Netzwerks dieser Immunzellen, welches zum entzündlichen Phänotyp des Alterns beitragen 
könnte.
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1. Introduction 
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1.1 Cardiovascular disease 
The term cardiovascular disease (CVD) comprises a group of disorders of the heart, brain 
vasculature, and blood vessels, such as ischaemic heart disease (or coronary artery disease), 
stroke, and hypertension (Mendis et al., 2011). CVD is the leading cause of mortality and 
disability worldwide, accounting for an estimated 31% of global deaths per year (World Health 
Organization, 2018).  
 
The main pathophysiological condition leading to CVD is atherosclerosis, a chronic 
inflammatory process that occurs in medium and large blood vessels (Mendis et al., 2011). The 
pathogenesis of atherosclerosis involves lipid deposition, activation of dysfunctional 
endothelium, and release of pro-inflammatory cytokines and chemoattractant molecules; 
subsequent leukocyte recruitment, activation and transmigration (primarily monocyte-derived 
macrophages that later form foam-cells, and T-cells); platelet aggregation; and smooth-muscle 
cell migration and proliferation as a result of cytokine and growth factor secretion (Tousoulis 
et al., 2014). Among the most important risk factors for atherosclerosis and CVD are advancing 
age and high atherogenic lipid burden, i.e. cholesterol and its lipoprotein carriers (Catapano et 
al., 2016; Grundy et al., 2018; Mendis et al., 2011). 
 
1.2 Statins 
Statins are the first line of treatment in the management of hyperlipidaemias and prevention of 
CVD (Catapano et al., 2016; Stone et al., 2014). Since their introduction in 1987, statin 
prescription has risen, as shown by several studies in different populations (Nolte et al., 2010; 
Salami et al., 2017; Vancheri et al., 2016). Thus, statins are positioned among the most 
prescribed drug classes worldwide, in a tendency that seems to be maintained. 
 
1.2.1 Pharmacological and pharmacokinetic aspects 
Statins are competitive inhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase enzyme, the rate-limiting enzyme in the mevalonate biosynthetic pathway. As a 
consequence, they block the biosynthesis of cholesterol in the liver, enhancing clearance of 
circulating low density lipoprotein (LDL)-cholesterol (Sirtori, 2014). Inhibition of the 
mevalonate pathway by statins also impairs biosynthesis of its other products, such as 
isoprenoid metabolites, important for the post-translational modifications of several proteins, 
and ubiquinone (Figure 1.1 A). 
 
First discovered as fungal secondary metabolites (Endo, 2010), statins are either classified 
according to their origin in natural/semi-synthetic (lovastatin, simvastatin and pravastatin), and 
synthetic statins (atorvastatin, rosuvastatin, fluvastatin, pitavastatin, and cerivastatin); or 
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according to their lipophilicity. They are administered as the active hydroxy-acid, except for 
lovastatin and simvastatin, which are lactone prodrugs (Gazzerro et al., 2012; Sirtori, 2014). 
The chemical structure and lipophilic properties of statins are summarised in Figure 1.1 B. 
 
A 
 
 
B 
 
Figure 1.1. General aspects of statins. The mevalonate pathway, simplified schema (A). Statins inhibit HMG-CoA 
reductase, the rate limiting enzyme of the pathway. PP, pyrophosphate. The structure of the 8 therapeutically 
approved statins (B). The lipophilic properties and standard daily dose are specified. *Withdrawn from the market. 
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1.2.2 Pleiotropic effects of statins 
Extended research has shown that statins exert beneficial effects independent from their lipid-
lowering action. In the cardiovascular system, these so called “pleiotropic” effects include 
improvement of endothelial function, inhibition of vascular inflammation and thrombogenesis, 
and atherosclerotic plaque stabilisation (Almeida and Budoff, 2019). Furthermore, statins 
showed immunomodulatory and antioxidant actions, neuroprotective effects, and beneficial 
effects in lipid-independent diseases, such as rheumatoid arthritis, multiple sclerosis, bone loss, 
and cancer (Gazzerro et al., 2012; Margaritis et al., 2014; Oesterle et al., 2017). 
 
Several cellular and molecular mechanisms underlie statin pleiotropy, the majority of them 
attributed to inhibition of Ras, Rho and Rac small GTPase function, as a result of reduced 
isoprenylation (Huacuja Álvarez et al., 2006). Studies have shown that statins increase the 
expression of the atheroprotective transcription factor Krüppel-like factor 2 (KLF2) and 
improve nitric oxide (NO) activity in the vascular endothelium, inhibit nuclear factor (NF)-κB 
transcriptional activity in different cell types, inhibit cell proliferation, decrease reactive oxygen 
species (ROS) generation, and inhibit the major histocompatibility complex (MHC) II in T-
cells, among other effects (Gazzerro et al., 2012; Margaritis et al., 2014; Oesterle et al., 2017). 
 
1.2.3 Statin-associated muscle symptoms 
It is generally considered that the benefits of statin therapy largely outweigh the risks of adverse 
effects (Collins et al., 2016), of which the most relevant are newly diagnosed type 2 diabetes 
mellitus, hepatotoxicity, and statin-associated muscle symptoms (SAMS) (Newman et al., 
2019). SAMS are a class effect, dose-dependent and not correlated to the hypolipidemic effect 
of the statin (Kobayashi et al., 2008; Vaklavas et al., 2009). They constitute one of the principal 
causes of non-adherence to treatment, in fact, muscle toxicity was the reason for cerivastatin 
withdrawal from the market in 2001 (Taha et al., 2014). With a prevalence of 5–29% in clinical 
practice, SAMS can range from mild myalgia without elevation of creatine kinase (CK) to, in 
very rare cases, fatal rhabdomyolysis (Grundy et al., 2018; Stroes et al., 2015).  
The molecular mechanisms that lead to muscle impairment are still not fully understood. 
Several HMG-CoA-related and non-related mechanisms have been proposed (recently 
reviewed by du Souich et al., 2017): isoprenoid depletion (particularly of GGPP) cause 
apoptosis and proteolysis mediated by inhibition of the protein kinase Akt and the 
transcriptional coactivator peroxisome-proliferator-activated receptor coactivator (PGC)-1α; 
direct impairment of mitochondrial respiration, ROS production, and calcium homeostasis in 
the myocyte also trigger apoptosis. Moreover, reduced resting chloride channel conductance 
and decreased lactate efflux could cause muscle fatigue. In addition to their myotoxicity, statins 
impair muscle regeneration via GGPP depletion, and impaired insulin-like growth factor-1 
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(IGF-1) signalling (Baba et al., 2008; Ogura et al., 2007; Trapani et al., 2012). Further research 
in the field can improve the understanding of these mechanisms and allow for identification of 
risks and biomarkers associated with SAMS (Muntean et al., 2017). 
 
1.3 The glucocorticoid-induced leucine zipper (GILZ) 
GILZ was first identified as a dexamethasone-inducible gene (Tsc22d3) encoding for a 137-
amino acid (aa) protein in murine thymocytes (D’Adamio et al., 1997). Later, other splice 
variants of murine GILZ were described, encoding for proteins of 201 aa, 43 aa, 80 aa 
(Soundararajan et al., 2007), and 234 aa (Bruscoli et al., 2010). Human GILZ is a 134-aa protein 
with 97% similarity in the coding region with its murine orthologue (Cannarile et al., 2001). 
Different transcript variants coding for other isoforms are also annotated for the GILZ gene and 
have been observed experimentally (NCBI “Gene”; Köberle et al., 2012).  
 
GILZ consists of three domains: The N-terminal domain (residues 1–75), a central leucine 
zipper (LZ) domain (residues 76–97), and the C-terminal domain, which includes a 
proline/glutamate-rich (PER) region (residues 98–137). The N- and C-terminal regions are 
responsible for the interaction of GILZ with its targets, while the LZ-domain mediates the 
protein homodimerization (Figure 1.2 Ayroldi et al., 2014; Fan and Morand, 2012a). 
 
 
Figure 1.2. GILZ structure and functional domains. Modified from (Ayroldi et al., 2014). 
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GILZ is ubiquitously expressed in human and mouse tissues (Cannarile et al., 2001; 
Soundararajan et al., 2007). Besides its immunomodulatory function, it plays multiple roles in 
other glucocorticoid (GC)-mediated as well as non-GC-mediated cellular processes. The anti-
inflammatory action of GILZ is mainly exerted via inhibition of NF-кB transcriptional activity, 
as well as interaction with activator protein (AP)-1. Anti-proliferative, anti-oncogenic, pro-
apoptotic and anti-apoptotic functions of GILZ in different cell types have also been reported 
(reviewed by Ayroldi et al., 2014). 
 
1.4 Aging and age-related diseases 
Aging, defined as the functional decline that occurs during the lifespan of an organism, 
constitutes a risk factor for several human pathologies (López-Otín et al., 2013). For instance, 
the prevalence and mortality associated with CVD is expected to grow exponentially, as the 
world population continues to age (Costantino et al., 2016). The recent field of geroscience 
intends to understand the mechanisms driving aging and age-related chronic disease, how they 
interact and overlap, in order to provide therapeutic opportunities to extend human lifespan by 
targeting aging itself (Kennedy et al., 2014). In this context, seven pillars of aging have been 
identified (Figure 1.3). These are not independent factors, but rather constitute an integrated 
network that, interestingly, converge on inflammation (Franceschi et al., 2018; Kennedy et al., 
2014). Indeed, longitudinal studies have shown a correlation between inflammation and 
longevity, capability, and cognition in the aged population (Arai et al., 2015). 
 
 
 
Figure 1.3. The seven pillars of aging. After Kennedy et al., 2014. 
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1.4.1 Inflammaging 
The changes in the immune system associated with aging, globally known as 
immunosenescence, affect both innate and adaptive immunity. Rather than solely detrimental, 
such changes represent an adaptive/remodelling response that results in dysregulated 
homeostasis not only of immunity, but of other systems that influence and are influenced by 
the immune system, like the nervous and endocrine systems (Fulop et al., 2018).  
 
The chronic, low-grade systemic inflammatory state observed with advancing age, termed 
“Inflammaging” (Franceschi et al., 2000), involves functional alteration of immune cells as a 
consequence of different mechanisms, including cellular senescence, oxidative stress, 
mitochondrial dysfunction, defective autophagy and mitophagy, inflammasome activation, and 
dysbiosis (Franceschi et al., 2018). Population studies have shown that aged individuals have 
elevated circulating levels of pro-inflammatory mediators/markers, such as tumour necrosis 
factor α (TNF-α), interleukin (IL)-6 and C-reactive protein (CRP), that correlate with increased 
risk of morbidity and mortality (Bandaranayake and Shaw, 2016; Minciullo et al., 2016). The 
global pro-inflammatory state, however, is not the only determinant of successful/unsuccessful 
aging, as a compensatory, anti-inflammatory response, is observed in parallel to inflammaging, 
particularly in very long-lived individuals (centenarians). The mediators associated with anti-
inflammaging include transforming growth factor (TGF)-β, IL-10, dehydroepiandrosterone 
(DHEA), and cortisol (Baylis et al., 2013; Minciullo et al., 2016). It is considered that, 
ultimately, the ability of the anti-inflammatory network to cope with and modulate chronic 
inflammation is determinant to either attain healthy aging and longevity, or for the onset of 
chronic inflammatory diseases. 
 
1.5 Glucocorticoid function and metabolism 
1.5.1 Regulation of glucocorticoid response and function 
Endogenous GCs are master regulators of several physiological functions, including 
metabolism, development, cardiovascular function, response to stress, and immune function 
(Kharwanlang and Sharma, 2017). The synthesis of GCs is regulated in a circadian manner, and 
in response to stressors (including pro-inflammatory cytokines), by the hypothalamic-pituitary-
adrenal (HPA) axis, a component of the neuroendocrine system (Gupta and Morley, 2014). 
Activation of the HPA axis starts with release of corticotropin-releasing hormone (CRH) and 
arginine vasopressin (AVP) from the hypothalamus, which stimulate the secretion of 
adrenocorticotropic hormone (ACTH) from the anterior pituitary gland. ACTH enters the 
circulation and stimulates synthesis of GCs through steroidogenesis in the adrenal cortex. 
Secreted GCs, in turn, cause a decrease in the release of CRH and ACTH, in a negative feedback 
loop (Figure 1.4 A). GCs circulate bound in a 95% to corticosteroid-binding globulin (CBG). 
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Free GCs can diffuse through cell membranes and exert their action by binding to the widely 
expressed glucocorticoid receptor (GR) through genomic mechanisms (transactivation, 
transrepression, and composite glucocorticoid response element (GRE) binding), or non-
genomic effects (Cain and Cidlowski, 2017). 
 
While the HPA axis controls systemic GC release, the bioavailability and activity of GCs is 
controlled at the intracellular, pre-receptor level, by two enzymes: 11β-hydroxysteroid 
dehydrogenase (11β-HSD) 1 and 2, that catalyse the interconversion of active cortisol and 
inactive cortisone (Chapman et al., 2013). 11β-HSD1 functions mainly as a reductase, 
catalysing the NADPH-dependent reduction of cortisone to cortisol in the endoplasmic 
reticulum, although it can also act as an NADP-dependent dehydrogenase, inactivating cortisol. 
11β-HSD2, on the contrary, functions solely as a NAD-dependent reductase (Figure 1.4 B). 
 
 
 
Figure 1.4. Regulation of cortisol levels. The HPA axis, see text for details (A). Intracellular levels of cortisol are 
controlled by the interconversion of cortisone and cortisol by 11β-HSD isozymes (B). In the endoplasmic reticulum 
(ER), 11β-HSD1 reduces cortisone to cortisol using the NADPH generated by hexose 6-phosphate dehydrogenase 
(H6PDH) as cofactor. H6PDH catalyses the conversion of glucose-6-phosphate (G6P) to 6-phosphogluconate 
(6GP). 
1.5.2 Glucocorticoids in inflammation 
Although GCs are well established anti-inflammatory agents in pharmacological therapy, they 
cannot be defined as strictly immunosuppressive in normal physiology. The anti-inflammatory 
action of GCs occurs at all stages of inflammation. During the alarm phase, GCs attenuate the 
secretion of pro-inflammatory mediators by inhibiting NF-кB and AP-1 activity, decrease 
histamine release by mast cells, and reduce vascular permeability. In the mobilization phase, 
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they attenuate leukocyte extravasation by reducing the secretion of chemokines and adhesion 
molecules. Finally, during the resolution phase, they promote an anti-inflammatory, phagocytic 
phenotype in macrophages, to allow for tissue clearance (Cain and Cidlowski, 2017). On the 
other hand, GCs can also increase the expression of genes associated with the detection of insult 
and initiation of the inflammatory response, i.e. pattern recognition receptors (PRRs), 
chemokine/cytokine receptors, and complement factors, in what is thought to be a mechanism 
to sensitise immune cells so that they respond rapidly and effectively to insult. Once the 
inflammatory response is triggered, elevated concentrations of GCs (in response to stress) 
restrain the extent of inflammation, suppress the adaptive immune response, and help restore 
homeostasis (Busillo and Cidlowski, 2013; Cain and Cidlowski, 2017). This biphasic 
immunostimulant/immunosuppressive action highlights the main role of endogenous GCs in 
regulation of immunity, and how the dysregulation of GC secretion and function (e.g. during 
chronic stress associated with aging) might directly impair immune function. 
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1.6 Aim of the present work 
Statins are the cornerstone of CVD prevention and treatment. As CVD remains the leading 
cause of morbidity and mortality worldwide, and a growing portion of the population already 
is or will be under statin treatment, the study of the molecular mechanisms that mediate their 
beneficial and deleterious effects remains of importance. In the first part of this work, we aimed 
to elucidate such mechanisms, focusing on the role of GILZ. First, its potential role in the onset 
of SAMS, the most common adverse effect associated with statin use, was investigated. 
Secondly, its potential role as an anti-inflammatory mediator of the pleiotropic effects of statins 
in vascular inflammation was evaluated. 
 
The aging population is at high risk of suffering from cardiovascular events, as well as other 
age-related diseases. Chronic inflammation is one of the pillars that underlie the functional 
decline associated with age, thus, identification of the pathways that control/fuel the so called 
“inflammaging” process is relevant for the design of preventive and therapeutic strategies for 
age-related diseases. Aim of the second part of this work was to evaluate the age-associated 
changes in gene expression and glucocorticoid metabolism across tissues, as well as in the 
myeloid compartment of mice, to improve the current understanding of the molecular 
mechanisms that modulate inflammaging.
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2. Materials and Methods 
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2.1 Chemicals and reagents 
Cell-culture grade dimethyl sulfoxide (DMSO), atorvastatin, simvastatin, cerivastatin, 
pravastatin, and mevalonic acid lithium salt were obtained from Sigma-Aldrich (St Louis, MO, 
USA). Simvastatin sodium salt, geranylgeranyl pyrophosphate (GGPP), and farnesyl 
pyrophosphate (FPP) were obtained from Cayman Chemicals (Ann Arbor, MI, USA). 20 mM 
statin stock solutions were prepared in DMSO and stored at -20 °C. Unless stated otherwise, 
experiments performed with simvastatin refer to the active acid form of the drug. 100 mM stock 
solution from mevalonic acid was prepared in sterile water and stored at -20 °C. Foetal bovine 
serum (FBS), horse serum, trypsin-EDTA, accutase, high glucose DMEM, and RPMI 1640 
were from Sigma-Aldrich. Penicillin/streptomycin and glutamine were from PAA (Pasching, 
Austria). MCDB 131 medium was from Thermo Fisher Scientific (Waltham, MA, USA). 
Endothelial Cell Growth Medium (ECGM) and endothelial cell growth medium 
SupplementMix were obtained from PromoCell (Heidelberg, Germany). DNA oligos and 
Sanger sequencing services were provided by Eurofins Genomics (Ebersberg, Germany). All 
other chemicals were obtained either from Sigma Aldrich or Carl Roth (Karlsruhe, Germany), 
unless stated otherwise. 
 
2.1.1 General Buffers 
PBS: 2.7 mM KCl, 1.8 mM KH2PO4, 137 mM NaCl and 10 mM Na2HPO4 in distilled water. 
The pH was adjusted to 7.4 and the solution was adjusted to a final volume of 1 l. PBST was 
prepared by adding 0.1% tween-20 to PBS. 
 
TBS: 20 mM Tris and 137 mM NaCl in distilled water. The pH was adjusted to 7.6 and the 
solution was adjusted to a final volume of 1 l. TBST was prepared by adding 0.1% tween-20 to 
TBS. 
 
TBE: 90 mM Tris, 90 mM H3BO3, 2 mM EDTA disodium in distilled water, in a final volume 
of 1 l. 
 
Sodium phosphate buffer, 1 mM, pH 5.6: 65.05 mg NaH2PO4∙H2O, 4.05 mg Na2HPO4 in 
distilled water. The pH was adjusted to 5.6 and the solution was adjusted to a final volume of 
500 ml. 
 
Electrophoresis buffer: 25 mM Tris, 192 mM glycine, 0.1% SDS in distilled water, to a final 
volume of 1 l. 
 
Blotting buffer: 25 mM Tris, 192 mM glycine, and 5% methanol in distilled water, to a final 
volume of 1 l.  
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2.2 Cell culture 
2.2.1 Cell lines 
C2C12 cells (ECACC 91031101) were maintained in high glucose DMEM (growth medium, 
GM) at a maximum confluency of 65%, HEK-293T cells (ATCC® CRL-3216) were 
maintained in high glucose DMEM, RAW 264.7 cells (ATCC® TIB-71) were maintained in 
RPMI 1640, and HMEC-1 cells (ATCC® CRL-3243) in MCDB 131 medium. All cell culture 
media were supplemented with 10% FBS, penicillin/streptomycin (100 U / 100 µg/ml), and 
2.0 mM glutamine, unless stated otherwise. For inducing differentiation of C2C12 into 
myotubes, confluent cell layers were cultured in high glucose DMEM supplemented with 2% 
horse serum, penicillin/streptomycin and glutamine (differentiation medium, DM), with 
medium change every other day. All cells were cultured at 37 °C in a humidified atmosphere 
with 5% CO2. Cells were subcultured according to the ATCC recommendations. Briefly, cells 
were washed with PBS and detached with trypsin-EDTA. Digestion was stopped with culture 
medium, the cell suspension was centrifuged for 5 minutes at 200 x g and resuspended in 
medium. The resulting suspension was used for seeding cells for experiments, and appropriate 
aliquots were used for passaging.  
 
2.2.2 Cell freezing / thawing 
For freezing, cells were washed and detached as for splitting. The cell suspension was 
centrifuged for 5 minutes at 200 x g and cells were resuspended in freezing medium (FBS with 
10% DMSO). Cells were aliquoted into cryovials, frozen at -80 °C for 2 days, and transferred 
to liquid nitrogen for long-term storage.  
For thawing, frozen cells were warmed up in a 37 °C water bath, and quickly transferred into 
pre-warmed medium. The resulting suspension was centrifuged for 10 minutes at 200 x g, the 
cell pellet was resuspended in culture medium and cells were cultured as described above. 
 
2.2.3 Primary cells 
Isolation of primary cells in the laboratory was performed with technical assistance from Theo 
Ranßweiler, Dr. Jessica Hoppstädter, and Anna Dembek. 
 
Human umbilical endothelial vein cells (HUVECs): HUVECs were isolated from umbilical 
cords as described previously (Weber et al., 2003). In brief, the umbilical cord vein was digested 
with a 0.01% collagenase A solution (#10103586001, Roche, Basel, Switzerland) for 45 
minutes. Cells were suspended in ECGM supplemented with endothelial cell growth medium 
SupplementMix, 10% FBS, penicillin/streptomycin (100 U / 100 µg/ml), and kanamycin 
(50 µg/ml), and plated in a 25 cm2 cell culture flask. On the next day, cells were washed twice 
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with PBS, the medium was renewed, and cells were cultured as described above. Cells were 
used for experiments in passages 2–3. 
 
Murine bone marrow-derived macrophages (BMMs): BMMs were isolated from male 
C57BL/6J wildtype (WT) or GILZ knockout (KO) mice, following a previously published 
method (Hoppstädter et al., 2015). In brief, femurs and tibias were flushed with RPMI 1640 
medium supplemented with penicillin/streptomycin. After centrifugation for 10 minutes at 
200 x g, the cell pellet was resuspended in hypotonic buffer (155 mM NH4Cl, 10 mM KHCO3 
and 0.1 mM EDTA disodium in distilled water, to a final volume of 1 l) for erythrocyte lysis, 
during 3 minutes in a 37 °C water bad. Cells were centrifuged and resuspended in RPMI 1640 
medium supplemented with 10% FBS (PAN Biotech, Aidenbach, Germany), 
penicillin/streptomycin, glutamine, and 50 ng/ml M-CSF (#99906, Biomol, Hamburg, 
Germany), plated in a 75 cm2 cell culture flask, and allowed to adhere overnight. Non-adherent 
cells were then transferred into a 175 cm2 cell culture flask and cultured for another 5 days 
before use in experiments. 
 
Murine peripheral blood leukocytes (PBL): whole blood from young and aged C57BL/6 
mice was collected in PBS-EDTA (5 mM EDTA in PBS) containing tubes, and centrifuged for 
20 minutes at 500 x g and 4 °C. The cell pellet was resuspended in 1 ml erythrocyte lysis buffer 
and incubated for 15 minutes on ice. After 5 minutes of centrifugation at 500 x g and 4 °C, the 
supernatant was discarded and the PBL pellet was frozen at -80 °C.  
 
Murine peritoneal macrophages (PMs): PMs were isolated from young and aged C57BL/6J 
mice by washing the peritoneal cavity with cold PBS-EDTA. The fluid was collected and 
centrifuged for 10 minutes at 350 x g and 4 °C. Cells were resuspended in RPMI-1640 medium 
supplemented with 10% FBS (PAN Biotech), penicillin/streptomycin, and glutamine, seeded 
in a 35 mm cell culture dish, and allowed to adhere for 2 hours. After this time, non-adherent 
cells were removed by washing with PBS and PMs were detached with accutase. The cell 
suspension was centrifuged, and the pellets were frozen at -80 °C. When used for treatment, 
cells were resuspended and plated in RPMI-1640 medium without FBS and, after removing the 
non-adherent cells at the end of 1 hour, treated as specified below. 
 
Flexor digitorum brevis (FDB) muscle fibres: FDB fibres were isolated from WT or GILZ 
KO C57BL/6J mice by Dr. Jessica Hoppstädter in the laboratory of Professor Carlo Riccardi 
(Department of Medicine, University of Perugia), following a protocol adapted from the 
literature (Keire et al., 2013; Park et al., 2014; Weisleder et al., 2012). The FDB muscles were 
dissected under a stereo microscope and digested in a 0.2% collagenase A solution in DMEM 
for 60 minutes. Then, the myofibres were carefully separated under a stereo dissecting 
microscope, dispersed in DMEM containing 10% horse serum by drawing through a series of 
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pipette tips with gradually decreasing diameter, and purified by sedimentation steps. Pure fibres 
were plated in laminin (#L2020, Sigma Aldrich)-coated cell culture dishes, and cultured in 
DMEM supplemented with 20% serum replacement 2 (#S9388, Sigma Aldrich), 1% horse 
serum, penicillin/streptomycin, and glutamine. 
 
Murine primary myoblasts: Primary myoblasts were isolated from hindlimbs of male 3-day-
old WT or GILZ KO C57BL/6J mice by Dr. Jessica Hoppstädter in the laboratory of Professor 
Carlo Riccardi (Department of Medicine, University of Perugia). The muscle was dissected and 
shredded, washed in PBS and digested with trypsin-EDTA for 60 minutes. After filtering 
through a 70 µm cell strainer, the cell suspension was diluted in DMEM supplemented with 
10% FBS and centrifuged for 20 minutes at 200 x g and 4 ºC. The resuspended cells were pre-
plated for 1 hour to allow fibroblast adhesion. Non-adherent cells were collected, centrifuged 
for 10 minutes at 200 x g and 4 ºC, resuspended in F-10-based primary myoblast growth 
medium (Ham’s F-10 nutrient mixture, #N6013, Sigma-Aldrich, supplemented with 20% FBS, 
penicillin/streptomycin, and glutamine), and plated onto collagen I (#C3867, Sigma-Aldrich)-
coated cell culture dishes. Further enrichment of the myoblasts was achieved by dislodging and 
pre-plating the cells onto collagen-coated dishes every fourth day for 1-2 weeks. Afterwards, 
myoblasts were cultured in growth medium (40% DMEM, 40% Ham’s F-10 nutrient mixture, 
20% FBS), supplemented with penicillin/streptomycin and glutamine. 
 
2.3 Bacterial culture 
The following E. coli strains were used as host organisms for plasmid amplification: 
 
TOP10 (Invitrogen, Carlsbad, CA, USA). Genotype: F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 nupG recA1 araD139 Δ(ara-leu)7697 galE15 galK16 rpsL(StrR) 
endA1 λ- 
 
GT116 (Invivogen, San Diego, CA, USA). Genotype: F¯ mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 ΔlacX74 recA1 endA1 Δdcm ΔsbcC-sbcD. 
 
Plasmids obtained from Addgene (Cambridge, MA, USA) were received and cultured in 
DH5α strain. Genotype: F- Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 
(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 λ-. 
 
Liquid cultures of bacteria were prepared in lysogeny broth medium (LB, 10% tryptone, 5% 
yeast extract, 5% NaCl, in water, pH 7.5), with or without antibiotic selection marker 
(ampicillin 100 µg/ml, Sigma-Aldrich), and cultured at 37 °C in an incubator shaker. Agar 
plates were prepared by adding 30% of agar to the culture medium. 
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2.3.1 Generation of competent E. Coli 
Competent E. coli were generated using the calcium chloride method. Briefly, 5 ml of an 
overnight culture were diluted to 100 ml with LB and allowed to grow to an OD600 = 0.4. The 
culture was then placed on ice for 30 min, centrifuged at 2,000 x g and 4 °C, and resuspended 
in 10 ml ice cold CaCl2 solution (75 mM CaCl2, 15% glycerol, in water). After 30 minutes of 
incubation on ice, cells were centrifuged at 2,000 x g and 4°C, resuspended in 2.5 ml CaCl2, 
aliquoted, and stored at -80 °C. 
 
2.3.2 Plasmid isolation 
Plasmids were isolated from overnight liquid cultures using either the High Pure Plasmid 
Isolation Kit (#11754777001, Roche), or the QIAprep Spin Miniprep Kit (#27106 Qiagen, 
Hilden, Germany), following the manufacturer’s instructions. 
 
2.4 Mice  
Mice were housed in a 12/12 hours light/dark circle with food and water ad libitum. GILZ KO 
mice were generated as previously described (Bruscoli et al., 2012; Hoppstädter et al., 2015). 
For aging studies, young (10 weeks) or aged (80–100 weeks) C57BL/6 mice were either non-
treated or treated with one intraperitoneal injection of 5 mg/kg LPS (#tlrl-smlps, InvivoGen, 
San Diego, CA, USA) or vehicle (DPBS) for 4 hours before sacrifice (approval number from 
animal welfare committee GB 3-2.4.2.2-06/2016). Tissues were removed and stored at -80 °C 
for RT-qPCR analysis. Serum, BMMs, PBLs, and PMs were also collected for analysis  
 
2.5 RNA isolation and reverse transcription 
Total RNA from cultured cells was isolated using the High Pure RNA Isolation Kit 
(#11828665001, Roche), following the manufacturer’s instructions. The RNA concentration 
was measured using a NanoDrop™ Lite spectrophotometer (Thermo Fisher Scientific). 
Samples with an A260/A280 ratio higher than 1.8 were used for further analysis. 
 
Total RNA from murine tissue was isolated using the QIAzol lysis reagent (#79306, Qiagen) 
following the manufacturer’s instructions. Residual genomic (g) DNA contamination was 
removed using the DNA-free™ DNA Removal Kit (#AM1906, Thermo Fisher Scientific). To 
verify the absence of gDNA, a SINE-PCR was performed using the GenScript Taq DNA 
polymerase (#E00007, GenScript Inc., Piscataway, NJ, USA). The primer sequences were: 
forward 5’-CTTCTGGAGTGTTTGAAGAC-3’, reverse 5’-CTGGAACTCACTCTGAAG 
AC-3’. The reaction was carried out in a T100 thermal cycler (Bio-Rad Laboratories, Hercules, 
CA, USA) using the following program: 
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Denaturation  5 min 94 °C  
Denaturation  1 min 94 °C  
 Annealing  1 min 56 °C  30 cycles  
Elongation  1 min 72 °C  
Final elongation  10 min 72 °C  
 
RNA was considered free of gDNA contamination when no product was detected by agarose 
gel electrophoresis. A 2% agarose gel containing 0.04% ethidium bromide was used for 
detection. Upon addition of a suitable volume of 10 x loading buffer (40 mM EDTA disodium, 
0.05% bromophenol blue, 0.05% xylene cyanol, 70% glycerol, in water ad 50 ml), DNA was 
loaded onto a gel and separated in TBE at 100 V. To determine the DNA fragment sizes, a 
50 bp ladder (#SM0372, Thermo Fisher Scientific) was used. The DNA bands were detected 
using a UV transilluminator and the software ArgusX1 (Biostep, Stollberg, Germany). 
 
RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit 
(#4368813, Thermo Fisher Scientific), in the presence of RNase inhibitor (RNaseOUT™, 
#10777019, Thermo Fisher Scientific), following the manufacturer’s instructions. 
 
2.6 Quantitative Polymerase Chain Reaction (qPCR) 
qPCR was performed on cDNA samples using the 5xHotFirePol EvaGreen qPCR Mix (no 
ROX, #08-25-00020, Solis BioDyne, Tartu, Estonia) in a 20 µl format. The primer sequences 
and annealing temperatures for each transcript are detailed in table 2.1. The reaction was 
conducted in a CFX96 touch™ Real-Time PCR detection system running the CFX Manager 
2.1 software (Bio-Rad Laboratories), using the following program: 
 
Denaturation 15 min 95 °C 
Denaturation 0:15 min 94 °C 
 Annealing 0:20 min 40 cycles Elongation 0:20 min 72 °C 
Plate read  
Melt curve 65 °C – 95 °C 
 
Data were analysed either by absolute quantification, using a standard curve of the PCR product 
cloned into the pGEM-T Easy vector (Promega, Madison, WI, USA), or with the comparative 
ΔΔCt method. Housekeeping genes were chosen based on the literature, or after evaluating the 
expression stability of at least three candidate genes under the experimental conditions, using 
the geNorm, NormFinder, and BestKeeper Software tools. Absolute amounts of transcript were 
normalised to the corresponding housekeeping genes. 
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Table 2.1. Primer sequences and annealing conditions for the transcripts evaluated in this study 
Gene 
NCBI 
Accession 
number 
Forward primer 
sequence 5´-3´ 
Reverse primer sequence 
5´-3´ 
µl primer 
[10 µM] / 
reaction 
Annealing 
T (°C) 
Human 
ACTB NM_001101.3 
TGCGTGACATTAAGG
AGAAG 
GTCAGGCAGCTCGTA
GCTCT 
0.5 60 
KLF2 NM_016270.2 
AGACCACGATCCTCCT
TGAC 
AAGGCATCACAAGCC
TCGAT 
0.5 60 
NOS3 
(eNOS) 
NM_00603.4 
CCTCACCGCTACAACA
TCCT 
ACGTTGATTTCCACTG
CTGC 
0.5 60 
TSC22D3 
(GILZ) 
NM_004089.3 
TCCTGTCTGAGCCCTG
AAGAG 
AGCCACTTACACCGCA
GAAC 
0.5 60 
Mouse 
Anxa1 NM_010730.2 
TGGAAAGCCCTTGGAT
GAAGT 
AAGTCCCTTCATGGCA
CCAC 
0.5 60 
Cdkn1a NM_007669.5 
GACCAGCCTGACAGA
TTTCTA 
TGGGCACTTCAGGGTT
TTCT 
0.5 60 
Cdkn2a NM_009877.2 
CGGGGACATCAAGAC
ATCGT 
GCCGGATTTAGCTCTG
CTCT 
0.5 60 
Cebpa 
NM_0012875
23.1 
TTCGGGTCGCTGGATC
TCTA 
TCAAGGAGAAACCAC
CACGG 
0.5 60 
Cebpb 
NM_0012877
39.1 
GGAGACGCAGCACAA
GGT 
AGCTGCTTGAACAAG
TTCCG 
0.5 60 
Csnk2a2 NM_009974.3 
GTAAAGGACCCTGTGT
CAAAGA 
GTCAGGATCTGGTAG
AGTTGCT 
0.8 60 
GR-β HM236293.1 
AAAGAGCTAGGAAAA
GCCATTGTC 
CTGTCTTTGGGCTTTT
GAGATAGG 
0.5 61 
H19 NR_130973.1 
CAGAGGTGGATGTGC
CTGCC 
CGGACCATGTCATGTC
TTTCTGTC 
0.5 60 
H6pd NM_173371.4 
ATAGATGCGGAAGGT
CGGGC 
ACCAGCGTGAGGATC
TCAGT 
0.5 60 
Hdac3 NM_010411.2 
GCATTCGAGGACATG
GGGAA 
TTTCGGACAGTGTAGC
CACC 
0.5 60 
Hsd11b1 NM_008288.2 
GGAACCCAGGAAGGA
AGATCA 
CAGGCAGGACTGTTCT
AAGAC 
0.5 60 
Hsd11b2 NM_008289.2 
AACCTCTGGGAGAAA
CGCAAG 
GGCATCTACAACTGG
GCTAAGG 
0.5 60 
Il1b NM_008361.3 
CCAAAAGATGAAGGG
CTGCTT 
GGAAGGTCCACGGGA
AAGAC 
0.5 60 
Il6 NM_031168.2 
AAGAAATGATGGATG
CTACCAAACTG 
GTACTCCAGAAGACC
AGAGGAAATT 
0.4 60 
Klf2 NM_008452.2 
CCTTGCACATGAAGCG
ACAC 
ACTTGTCCGGCTCTGT
CCTA 
0.5 60 
Mkp1 NM_013642.3 
CTCCAAGGAGGATAT
GAAGCG 
ACTAGTACTCAGGGG
GAGGC 
0.5 60 
Mmp9 NM_013599.3 
GCCGACTTTTGTGGTC
TTCC 
TACAAGTATGCCTCTG
CCAGC 
0.5 60 
Nr3c1 NM_008173.3 
AAAGAGCTAGGAAAA
GCCATTGTC 
TCAGCTAACATCTCTG
GGAATTCA 
0.5 61 
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Ppia NM_008907.1 
GGCCGATGACGAGCC
C 
TGTCTTTGGAACTTTG
TCTGC 
0.5 58 
Rn18s NR_003278.3 
AGGTCTGTGATGCCCT
TAGA 
GAATGGGGTTCAACG
GGTTA 
0.5 61 
Sgk1 
NM_0011618
45.2 
GAGGCCATGTGTCAAT
CATGC 
TTCTTTCACTTCACAC
CCAGGTT 
0.5 60 
Sirt1 NM_019812.3 
TGGAGCAGGTTGCAG
GAATC 
GGCACCGAGGAACTA
CCTGAT 
0.5 60 
Tnf NM_013693.2 
CCATTCCTGAGTTCTG
CAAAGG 
AGGTAGGAAGGCCTG
AGATCTTATC 
0.5 60 
Tsc22d3 NM_010286.4 
GGGATGTGGTTTCCGT
TAAACTGGA 
TGCTCAATCTTGTTGT
CTAGGGCCA 
0.4 61 
Tsc22d3 NM_010286.4 
GCTGCTTGAGAAGAA
CTCCCA 
GAACTTTTCCAGTTGC
TCGGG 
0.5 60 
Zebrafish 
actb2 NM_181601.4 
AAATTGCCGCACTGGT
T 
ACGATGGATGGGAAG
ACA 
0.5 60 
elf1 NM_131159.2 
CTCAAATGGCATGGAT
GTTGCCCA 
GGTCTTGGTTTGCGCA
CTTTGGTT 
0.5 60 
fbxo32 NM_200917.1 
GGAGCACCAAAGAGC
GTCAT 
AGTTGGGACTTGGCG
ATGAG 
0.5 60 
hatn10 NA 
TGAAGACAGCAGAAG
TCAATG 
CAGTAAACATGTCAG
GCTAAATAA 
0.5 60 
rn18s KY486501.1 
CCGCTAGAGGTGAAA
TTCTTG 
CAGCTTTGCAACCATA
CTCC 
0.5 60 
tsc22d3 NM_200569.2 
AACAACCAGCTGGAG
CGCGAA 
GCAGAGCCCGTGCTG
CTGTATT 
0.5 60 
 
2.7 Western blot 
Protein lysates were prepared either in SB lysis buffer (50 mM Tris-HCl, 1% SDS, 10% 
glycerol, 5% β-mercaptoethanol, 0.004% bromophenol blue, in water) or RIPA buffer (50 mM 
Tris-HCl, 1% triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 150 mM NaCl, in water), 
supplemented with a protease inhibitor cocktail (cOmplete® Mini, # 04693124001, Roche). 
Samples were sonicated for 5 s and stored at -80 °C for further analysis. The protein 
concentration in RIPA lysates was measured using the Pierce™ BCA Protein Assay Kit 
(#23225, Thermo Fisher Scientific). 
 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using polyacrylamide 
gels (4% stacking gel and 12% resolving gel) and the Mini PROTEAN system (Bio-Rad 
Laboratories). Samples were thawed on ice and denatured at 95 °C for 5 minutes before loading 
into the gel. For samples prepared in RIPA buffer, an appropriate volume of loading buffer 
(Roti®-Load 1, #K929, Carl-Roth) was added before denaturation. To estimate protein size, a 
prestained protein ladder was run in parallel to the samples (PageRuler™, #26616, Thermo 
Fisher Scientific). Samples were transferred onto an Immobilon®-FL PVDF membrane 
(#IPFL00010, Merck, Darmstadt, Germany) using a Mini Trans-Blot® cell (Bio-Rad 
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Laboratories). After blotting, the membrane was allowed to air-dry. Afterwards, it was soaked 
in methanol and rinsed with distilled water, before continuing with the immunodetection.  
 
2.7.1 Near-Infrared detection 
The membrane was blocked for 1 to 2 hours in blocking buffer for fluorescent western blotting 
(RBB, #MB-070, Rockland Immunochemicals, Limerick, PA, USA) before incubation with 
primary antibody at 4 °C overnight. Antibody sources and dilutions are indicated in table 2.2. 
The membrane was washed 4 times for 5 minutes with PBST (or TBST) and incubated with the 
appropriate IRDye-conjugated secondary antibody, at room temperature for 90 minutes. After 
washing, the signal was detected using an Odyssey® Near-Infrared Imaging System and 
software (LI-COR Biosciences, Lincoln, NE, USA). 
 
2.7.2 Chemiluminescent detection 
Chemiluminescent immunodetection was performed in the laboratory of Professor Carlo 
Riccardi (Department of Medicine, University of Perugia), using the HRP-coupled secondary 
antibodies listed in table 2.2 and the Clarity™ Western ECL Blotting Substrate (Bio-Rad 
Laboratories), according to the manufacturer’s instructions. 
 
Table 2.2. Antibodies used in this study for western blot 
Antibody Dilution Cat. Number Supplier 
Mouse anti α-tubulin [DM1A] 
mAb 
1:1,000 in 5% milk powder 
– PBST 
T 9026 Sigma-Aldrich 
Polyclonal goat anti 11β-HSD1 1:400 in RBB AF3397 
R&D Systems, 
Minneapolis, MN, USA 
Rat anti GILZ [CFMKG15] 
mAb 
1:1,000 in 5% milk powder 
– TBST 
14-4033-80 Thermo Fisher Scientific 
Mouse anti GADPH [OTI2D9] 
1:2,000 in 5% milk powder 
– TBST 
TA802519  
OriGene Technologies, 
Rockville, MD, USA  
Mouse anti Akt (pan) [40D4] 
mAb 
1:2,000 in 5% milk powder 
– TBST 
2920 
Cell Signalling 
Technology 
Danvers, MA, USA 
Rabbit anti phospho-Akt 
(Ser473) 
[D9E)] XP® mAb 
1:2,000 in 5% milk powder 
– TBST 
4060 
Polyclonal rabbit anti phospho-
FoxO3a (Ser253) 
1:2,000 in 5% milk powder 
– TBST 
9466 
Mouse anti FoxO3a [D12] 
mAb 
1:1,000 in gelatine buffer 
(0.75% gelatine A, 0.1% 
tween-20, 20 mM Tris, 
137 mM NaCl, pH 7.5) 
sc-48348 X 
Santa Cruz Biotechnology 
Dallas, TX, USA 
Mouse anti myogenin [5FD] 
mAb 
1:200 in TBST sc52903 Santa Cruz Biotechnology 
Polyclonal rabbit anti cleaved 
Caspase-3 
1:1,000 in TBST 
ALX-210-
807-C100 
Enzo Life Sciences 
Farmingdale, NY, USA 
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IRDye® 680RD goat anti 
rabbit IgG 
1:10,000 in RBB 926-68071 
LI-COR Biosciences, 
Lincoln, NE, USA 
IRDye® 800CW goat anti 
mouse IgG 
1:10,000 in RBB 926-32210 
IRDye® 800CW donkey anti 
goat IgG 
1:10,000 in RBB 926-32214 
Goat anti rat IgG (H+L), HRP 1:5,000 in TBST 31470 
Thermo Fisher Scientific Goat anti mouse IgG (H+L), 
HRP 
1:5,000 in TBST 31430 
Goat anti rabbit IgG, HRP 1:10,000 in TBST 12-348 Merck 
 
2.8 Cytotoxicity measurement 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay was 
used to determine cell viability after statin treatment. Cells were seeded in 96-well plates at a 
density of 1x104 cells/well (or 2x104 cells/well for C2C12 differentiation), allowed to adhere 
overnight, and treated with test compounds at the indicated concentrations. Cells incubated 
without any treatment were used as growth controls, cells incubated with solvent at the 
maximum concentration present in the assay (0.25%) served as negative controls, and wells 
with treatment but without cells were used as blank. At the end of treatment, cells were 
incubated for 3 hours with MTT solution (0.5 mg/ml in medium) and lysed. The absorbance 
was measured at 550 nm in a microplate reader (XFluor4 SunriseTM, TECAN), using a reference 
wavelength of 690 nm. The relative viabilities were calculated related to the negative control; 
the comparison between the viability of growth control and negative control showed that the 
solvent had no statistically significant effect on cell viability (data not shown). 
 
For evaluating the cell viability in FDBs treated with statin, fibres isolated from 2 mice were 
pooled and treated with test compounds at the indicated concentrations. At the end of treatment, 
the number of living and non-living myofibres was evaluated using the trypan blue exclusion 
method. 
 
2.9 Effects of statins on C2C12 differentiation 
C2C12 myoblasts were seeded at a density of 1.0x105 cells/well in 24-well plates and induced 
to differentiate in the absence or presence of non-toxic concentrations of atorvastatin (5 µM), 
pravastatin (50 µM), simvastatin (1 µM) and cerivastatin (0.1 µM) for 5–6 days. Myotube 
formation was evaluated via Jenner-Giemsa staining and IF of myosin heavy chain. Similarly, 
primary myoblasts of WT and GILZ KO mice, as well as stable C2C12scr or C2C12shGILZ cells 
(see 2.15) were induced to differentiate in the absence or presence of statins. 
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2.10 Jenner-Giemsa staining 
To measure the myogenic differentiation of C2C12 myotubes Jenner-Giemsa staining was 
performed, following a previously published protocol (Veliça and Bunce, 2011). In brief, cells 
were fixed in ice-cold methanol for 5 minutes, air-dried, and stored at 4 °C until analysis. For 
staining, wells were incubated with Jenner’s stain solution (Santa Cruz Biotechnology; diluted 
1:3 in 1 mM sodium phosphate buffer pH 5.6) for 5 minutes at room temperature, washed with 
distilled water, and subsequently incubated with Giemsa solution (Carl Roth, diluted 1:20 in 
the same buffer) for 10 minutes at room temperature. Wells were observed in a phase contrast 
microscope equipped with a digital camera (ZEISS Axiovert 40 CFL with Canon EOS 400D), 
and each well was photographed in 3 randomly selected regions. Images were analysed using 
the free image-processing software Fiji (“Fiji Is Just ImageJ”, Schindelin et al. 2012). 
 
2.11 Immunofluorescence 
Myosin heavy chain immunofluorescence (MHC IF) was performed on C2C12 myotubes. Cells 
were cultured and differentiated onto glass coverslips that were previously treated for 10 
minutes in a 1:1 mixture of 70% ethanol and 0.1 N HCl (Andrés and Walsh, 1996). At the end 
of treatment, cells were pre-fixed by adding paraformaldehyde solution (4% in PBS) directly 
into the culture medium. After 2 minutes, the pre-fixation culture medium was replaced with 
paraformaldehyde solution and cells were fixed for 15 minutes at room temperature. Cells were 
washed with PBS and permeabilized with an 0.2% triton X-100 solution in PBS for 10 minutes 
at room temperature, washed, blocked in a 5% BSA solution in PBS for 1 hour at room 
temperature, and incubated with primary monoclonal anti-myosin heavy chain antibody (MF20, 
deposited by Donald A. Fischman to the Developmental Studies Hybridoma Bank, The 
University of Iowa, Department of Biology, Iowa City, IA, USA) diluted 1:50 in dilution buffer 
(1% BSA in PBS), at 4 °C overnight. After washing, cells were incubated with Alexa Fluor® 
488 goat anti-mouse secondary antibody (#A11017, Thermo Fisher Scientific) diluted 1:800 in 
dilution buffer, for 1 hour at room temperature. Then, cells were washed and counterstained 
with DAPI (#D9542, Sigma-Aldrich) for 15 minutes at room temperature, mounted with 
FluorSave™ (Merck) and observed with an Axio Observer Z1 epifluorescence microscope, 
equipped with an AxioCam Mr3 and AxioVision software (Zeiss, Oberkochen, Germany). 
Photographs from randomly selected regions were analysed using the Fiji software, and the 
fusion index was calculated as the percentage of total nuclei incorporated into myotubes, 
defined as myosin-expressing cells containing 3 or more nuclei. 
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2.11.1 Whole-zebrafish immunofluorescence 
Whole zebrafish embryos were stained following a protocol based on the literature (Cao et al., 
2009). Zebrafish embryos were fixed in paraformaldehyde solution at 4 °C overnight, and then 
stored in methanol at -20 °C for at least four hours. Embryos were permeabilized in acetone for 
30 minutes at -20 °C, washed, blocked in a 1% BSA solution in PBST for 2 hours at room 
temperature, and incubated with primary monoclonal anti-myosin heavy chain antibody (F59, 
deposited by Frank E. Stockdale to the Developmental Studies Hybridoma Bank, The 
University of Iowa, Department of Biology, Iowa City, IA, USA) diluted 1:100 in blocking 
buffer at 4 °C overnight. After washing in PBST, the embryos were incubated with Alexa 
Fluor® 594 goat anti-mouse secondary antibody (1:200; # A-11005 Thermo Fisher Scientific) 
at room temperature for 4 hours, washed again, and observed on a Leica SP8 Confocal 
microscope using the 40X magnification. 
 
2.12 GILZ induction under statin treatment 
To evaluate the ability of statins to induce GILZ in different cell types, HUVECs and C2C12 
cells were seeded in 12-well plates at a density of 1.5x105 and 1.0x105 cells/well, respectively, 
and BMMs were seeded at 2.5x105 cells/well in 24-well plates. Cells were treated with 3 µM 
atorvastatin and frozen at different time points for RT-qPCR analysis. 
 
In a second set of experiments, C2C12 or primary murine myoblasts were seeded at 
2.0x105 cells/well in 12-well plates and induced to differentiate in the absence or presence of 
non-toxic concentrations of atorvastatin (5 µM), pravastatin (50 µM), simvastatin (1 µM) and 
cerivastatin (0.1 µM) for up to 72 hours. Cells were frozen at different time points for RT-qPCR 
or western blot analysis.  
 
For evaluating the effect of toxic concentrations of statins on GILZ expression levels, C2C12 
myoblasts (5x104 cells/well) and 72-hour myotubes (1x105 cells/well) seeded in 24-well plates 
were treated with 50 µM statins for 6 hours, in the absence or presence of mevalonate (100 µM). 
Gene expression was evaluated via RT-qPCR, and protein via western blot. Primary murine 
myoblasts were similarly treated with atorvastatin and harvested for western blot analysis. In 
an analogue experiment, C2C12 myoblasts were treated with statin in the absence or presence 
of GGPP and FPP (10 µM). 
 
HUVECs were seeded in 24-well plates at 7x104 cells/well and treated with statins in the 
absence or presence of mevalonate (100 µM) for 24 hours. HMEC-1 cells were seeded in 24-
well plates at a density of 1x105 cells/well and treated with statins for 24 hours. Cells were 
frozen for RT-qPCR analysis. 
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2.13 Gene expression in zebrafish embryos under statin treatment 
Zebrafish embryos from the AB wildtype strain were obtained from the laboratory of Professor 
Rolf Müller (Helmholtz Institute for Pharmaceutical Research Saarland). The developmental 
stage was determined by embryo morphology, in hours post fertilization (hpf, Kimmel et al. 
1995) by observation under a stereo microscope. To examine the effects of statins, embryos at 
19–22 hpf were sorted and placed at a density of 2–3 embryos/cm2 in 6-well plates, and 
incubated at 28 °C in Danieu’s solution (17 mM NaCl, 2.0 mM KCl, 1.5 mM HEPES pH 7.1–
7.3, 1.8 mM Ca(NO3)2, 1.2 mM MgSO4, 1.2 µM methylene blue, in water) containing 1 µM 
statin or solvent control. 12 hours after treatment, 10–20 embryos were pooled, flash-frozen in 
liquid nitrogen, and stored at -80 °C for RNA isolation and RT-qPCR analysis.  
 
2.14 Chromatin immunoprecipitation (ChIP) 
The ChIP assay was performed by Dr. Jessica Hoppstädter in the laboratory of Professor Carlo 
Riccardi (Department of Medicine, University of Perugia), using the EZ-ChIP™ Kit (#17-371, 
Merck) according to the manufacturer’s instructions. In brief, C2C12 cells were fixed in 1% 
paraformaldehyde for 10 minutes, lysed, and sonicated on ice. Precleared lysates from 1x106 
myoblasts in a volume of 100 µl were incubated overnight at 4 C° with 10 µg monoclonal anti-
FoxO3 antibody (D12, #sc-48348 X, Santa Cruz Biotechnology) or 10 µg normal mouse IgG 
(#12-371B, Merck). Immunocomplexes were purified, and qPCR analysis was performed using 
the SYBR® Select Master Mix (#4472908, Thermo Fisher Scientific) and The Applied 
Biosystems 7300 qPCR system to determine the abundance of specific Gilz promoter regions. 
The primers used to quantify forkhead response elements (FHRE)-containing sequences and a 
non-FHRE sequence within the Gilz promoter are listed in table 2.3. 
 
Table 2.3. Primers used in the ChIP assay 
 
Forward primer sequence 5´-3´ Reverse primer sequence 5´-3´ 
FHRE1 TGGCCCAGTTAAACCACATCC GCTGAACTGTTTACAGTCCCTGA 
FHRE2 TAACCGTGTAAACAGGAGCCAG GGAACTCCTGGGGAAATCCTA 
FHRE3 AGCATGGGCAGAAAAAGGAATAAG CTGGTTTGGTTGGTGTAAACAGT 
FHRE4 (IRE, insulin-
response element,) 
AGAGCTTTCTTGGTCTGAGAGAAT AATTTTGAGGTGAGTAGCAGTAGT 
non-FHRE GTATTCGGCCTTCTCCTTGC CTGCTGCGTGGTGAAAAACA 
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2.15 Lentiviral transductions and stable cell line generation 
All lentiviral plasmids were obtained from Addgene. The packaging plasmid psPAX2 
(#12260), and the envelope plasmid pMD2.G (#12259), were a gift from Didier Trono. FUW-
tetO-loxP-hKLF2 was a gift from Rudolf Jaenisch (#60850, Theunissen et al., 2014). The 
pLKO.1-TRC cloning vector was a gift from David Root (#10878, Moffat et al., 2006). 
pLKO.1-scramble shRNA was a gift from David Sabatini (#1864, Sarbassov et al., 2005). 
LentiCas9-Blast was a gift from Feng Zhang (#52962, Sanjana et al. 2014).  
 
Two different sequences of short hairpin (sh) RNA targeting murine GILZ were used for 
generating lentiviral particles. shGILZ1 (5’-GGAGTACTGACTGGTCTCTTA-3’) was 
designed using the siRNA Wizard™ v3.1 software tool (InvivoGen). shGILZ2 (5’-ACAGCTT 
CACCTGACAATG-3’) was previously published (Bruscoli et al., 2010). Sequences were 
cloned into the pLKO.1-TRC cloning vector, following the protocol available from Addgene 
(Addgene, 2006), with minor modifications. In brief, the cloning vector was digested with 
AgeI-HF and EcoRI-HF (New England BioLabs, Ipswich, MA, USA) and purified from an 
agarose gel using the NucleoSpin® Gel and PCR Clean-up Kit (#740609, Macherey-Nagel, 
Düren, Germany). The annealed oligos were then ligated into the vector using T4 DNA ligase 
(#M0202, New England BioLabs) overnight at room temperature. The ligation mix was 
transformed into GT116 E. coli, and ampicillin-resistant clones were screened for inserts by 
sequencing, using the pLKO.1 sequencing primer (5’-GACTATCATATGCTTACCGT-3’). 
 
2.15.1 Lentivirus generation 
Lentiviral particles were produced following Addgene’s protocol. Briefly, 5x105 HEK-293T 
cells plated onto 6-cm cell culture dishes in medium without antibiotics were transfected at 50–
80% confluency with the transfer, packaging and envelope plasmids (1000:750:250) using the 
fuGENE® 6 Transfection Reagent (#E2691, Promega). 12–15 hours after transfection, the 
medium was replaced with complete DMEM. The lentivirus-containing media were then 
harvested at 24 and 48 hours, pooled, centrifuged at 200 x g for 5 minutes, aliquoted, and stored 
at -20°C. 
 
2.15.2 Lentiviral titre  
Non-biological titration of the lentiviral vectors was performed by determining the viral particle 
content in the harvested supernatants, using a protocol adapted from the literature (Geraerts et 
al., 2006; Scherr et al., 2001). Genomic viral RNA was purified from 200 µl of freshly harvested 
lentivirus stock using the High Pure Viral RNA Kit (#11858882001, Roche), following the 
manufacturer’s instructions. After digestion of residual DNA with the DNA-free™ DNA 
Removal Kit (Thermo Fisher Scientific), 10-fold serial dilutions of the purified viral RNA were 
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reverse transcribed and amplified via qPCR, using primers for the 5’LTR region (forward 5’-
AGCTTGCCTTGAGTGCT TCA-3’, reverse 5’-TGACTAAAAGGGTCTGAGGGA-3’), and 
the 5’-end of the gag gene (forward 5’-GGAGCTAGAACGATTCGCAGTTA-3’, reverse 5’-
TGTAGCTGTCCCAGTATTTGTC-3’). The copy number (viral particles, VP) contained in 
the supernatant was calculated from comparison against a plasmid standard curve, and the titre 
calculated as viral particles per ml of supernatant (VP/ml). 
 
The biological titration of the vectors was performed either via limiting dilution, following the 
protocol developed by the MISSION® RNAi Team (Sigma-Aldrich); or by qPCR, following a 
procedure modified from the protocol of the Laboratory of Virology and Genetics at the EPFL 
(École Polytechnique Fédérale De Lausanne), as follows: HEK-293T cells were seeded in 12-
well plates at a density of 8x104 cells/well and transduced with increasing amounts of lentiviral 
supernatant in the presence of 8 µg/ml polybrene (#H9268, Sigma-Aldrich). 96 hours after 
transduction, gDNA was extracted using the GenElute Mammalian gDNA Miniprep Kit 
(#G1N70, Sigma Aldrich) according to the manufacturer’s recommendations, and qPCR of 
5’LTR and gag was performed, using ACTB as housekeeping gene. For each dilution, the HIV 
copy number integrated per genome was calculated as the ratio of 5’LTR or gag copies to 
ACTB, and the viral titre was determined as the number of transducing units per ml of 
supernatant (TU/ml).  
 
For each lentivirus, the ratio from biological to non-biological titre was established and used 
for estimation of the functional titre (TU/ml) for all further preparations that were only titrated 
via the gRNA method. This functional titre was then used to determine the volume of viral 
supernatant needed for infecting cells at a given multiplicity of infection (MOI, defined as the 
number of TU per cell). 
 
2.15.3 Antibiotic kill curve 
The optimal concentration of antibiotic needed for selection of transduced cells was determined 
by performing an antibiotic kill curve. In brief, cells seeded at the same relative densities used 
for transduction in 24-well plates, were treated with increasing antibiotic concentrations. Cells 
were cultured with medium change every-other day and observed daily. The minimum 
concentration of antibiotic that resulted in complete cell death after 3–5 days was chosen for 
selection in the experiments. 
 
To determine whether the cells were able to grow starting as single cells, the kill curve was 
performed on a 96-well plate, in a matrix that combined decreasing concentrations of antibiotic 
(in rows) with decreasing cell numbers (in columns), from 1,000 to 1 cell/well. Cells were 
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considered to be able to grow as single clones when growth was observed after 10 days in the 
antibiotic control wells containing less than 4 cells on average. 
 
2.15.4 Generation of C2C12shGILZ stable cell lines 
Stable, polyclonal C2C12 cell lines were generated by reverse transducing 7.5x104 cells in 6-
well plates with scramble shRNA, shGILZ1, or shGILZ2 lentiviral particles at an MOI of 10 in 
the presence of polybrene, following the protocol for generation of stable cell lines available 
from Addgene. 24 hours after transduction the medium was changed, and 48 hours after 
infection puromycin (2 µg/ml, #540411, Merck) was added to select for transduced cells. The 
puromycin resistant cells were expanded for 2 to 3 weeks, after which they were harvested for 
analysis of gene and protein expression, and cell stocks were frozen. Further culture and 
experiments were done in 1 µg/ml puromycin-containing medium. A non-transduced control 
was run in parallel to confirm no viable cells were present after selection. 
 
2.15.5 KLF2 overexpression 
The FUW-tetO-loxP-hKLF2 transfer vector uses the Tet-On system to allow for doxycycline-
inducible overexpression of human KLF2. For overexpression in HUVECs, cells were seeded 
at 2x104 cells/well in a 24-well plate and transduced with hKLF2 lentivirus at an MOI of 10 
and 20 in the presence of polybrene. 24 hours after transduction, medium containing 2 µg/ml 
doxycycline (#ab141091, Abcam, Cambridge, UK) was added to the cells, to induce expression 
of the transgene. 72 hours after doxycycline addition, cells were harvested for RT-qPCR 
analysis. 
 
2.15.6 Generation of RAW 264.7Cas9 cells 
A RAW 264.7 macrophage cell line stably expressing Cas9 was generated for further use in 
CRISPR/Cas9 mediated gene editing experiments (see 2.18), following a protocol adapted from 
the literature (Joung et al., 2017). 5x105 cells were placed in a 6-well plate, Cas9 lentiviral 
particles were added at an MOI of 0.4 in the presence of polybrene, and cells were spinfected 
by spinning the plate at 1,000 x g for 2 hours at 33 °C. After 24 hours the medium was changed, 
and 48 hours after infection blasticidin S (12.5 µg/ml, #10264913, Fisher Scientific) was added 
to select for transduced cells. The blasticidin resistant cells were expanded for 2 to 3 weeks, 
after which cells stocks were frozen. A non-transduced control was run in parallel to confirm 
no viable cells were present after selection. 
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2.16 Short interfering (si) RNA-mediated gene knockdown 
For silencing KLF2 expression in HUVECs, 5x104 cells were transfected in a 24-well format 
with an siPOOLTM targeting the KLF2 gene, or a negative control siPOOLTM (siTools Biotech, 
Planegg/Martinsried, Germany), using the riboxxFECT transfection reagent (Riboxx, 
Radebeul, Germany). A reverse transfection protocol, according to the manufacturer’s 
instructions, was followed. The final concentration of siRNA was 3–10 nM. 
 
2.17 Morpholino-mediated Gilz silencing and mRNA-mediated overexpression in 
zebrafish 
The gene silencing/overexpression experiments in zebrafish were performed by the research 
group of Professor William K.F. Tse (Faculty of Agriculture, Kyushu University, Fukuoka, 
Japan). Zebrafish from the AB wildtype strain were raised and staged as previously described 
(Kimmel et al., 1995). All experimental procedures were approved by the Animal Experimental 
Committee, Kyushu University. 
 
2.17.1 Morpholino (MO) design and mRNA synthesis 
The Gilz MO and mRNA experiments were performed as previously published (Tse et al., 
2013). The sequence of tsc22d3 MO, targeting the ATG site, was 5′-GATTTTTGAACATCTC 
CGTGCTCAT-3′ (Gene Tools, Philomath, OR, USA). Its efficiency and specificity were 
confirmed by splicing MO, mRNA rescue, and Western blot analysis. 
 
tsc22d3 mRNA was amplified from full-length cDNA using Pfu DNA polymerase (Agilent 
Technologies, Santa Clara, CA, USA) and the following primers: forward 5′-
CCGAATTCATGAGCACAGAGATGTTCAA-3′, reverse 5′-CCCTCGAGTTATACAGCAG 
AGCCCCGT-3′, that contain EcoRI and XhoI restriction sites, respectively. The digested PCR 
products were ligated into the pCS2+ vector to generate the pCS2+tsc22d3 expression 
construct. The construct vector was linearized by digestion with NotI, and capped RNA was in 
vitro transcribed with the mMESSAGE mMACHINE™ SP6 Transcription Kit (#AM1340, 
Thermo Fisher Scientific), following the manufacturer’s instructions. 
 
2.17.2 MO and mRNA Injection  
Two pmol of tsc22d3 MO or 1,200 pg of mRNA were injected into 1- or 2-cell stage embryos. 
Embryos from 4 different fish pairings were used for each injection. At 24 hpf, embryos were 
collected and fixed for whole-mount immunofluorescence staining, as described under 2.11. 
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2.18 CRISPR/Cas9-mediated GILZ knockout 
The clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR-associated 
(Cas) 9 technique was used to disrupt the GILZ gene in HMEC-1 and C2C12 cells, using a 
transient transfection and clonal expansion approach. Validated synthetic TrueGuide™ single 
guide (sg) RNAs were obtained from Thermo Fisher Scientific. Target sequences were for 
TSC22D3 5’-ACTTACACCGCAGAACCACC-3’, and for Tsc22d3 5’-GATGTACGCTGTG 
AGAGAGG-3’. 
 
Cells at 30–70% confluency were transfected in a 12-well format with the synthetic sgRNA and 
a recombinant Cas9 protein (TrueCut™ Cas9 Protein v2, #A36496, Thermo Fisher Scientific), 
using the Lipofectamine™ CRISPRMAX™ Cas9 transfection reagent (#CMAX00001, 
Thermo Fisher Scientific), following the manufacturer’s instructions. 48 hours after 
transfection, cells were detached and counted. A fraction of the cells was used for clonal 
expansion, following the limiting dilution cloning procedure for HMEC-1 (seeding cells at 
0.8 cells/well in 96-well plates), or using cloning discs for isolation of single colonies from 
C2C12 seeded at low density (50, 250, 1,000 and 5,000 cells) in 6 cm cell culture dishes 
(Domann and Martinez, 1995). The remaining cells were used for gDNA extraction and 
verification of editing efficiency. The surviving clones after clonal expansion were harvested 
for gDNA extraction, PCR amplification of the edited region and sequencing analysis, 
amplified and kept either in culture or frozen, until confirmation of the knockout was achieved.  
 
2.18.1 Verification of editing efficiency 
The T7E1 endonuclease assay was performed on gDNA from control and transfected cells to 
verify the CRISPR genome editing in the mixed population. The assay is based on the ability 
of T7E1 to cleave mismatched DNA heteroduplexes, formed between WT and CRISPR-
mutated DNA strands after denaturation and reannealing of a PCR product amplified from the 
genomic target region. To this end, the Alt-R™ Genome Editing Detection Kit (#1075931, 
Integrated DNA Technologies, Skokie, IL, USA) was used according to the manufacturer’s 
instructions. The primers used for PCR amplification of the edited region were: TSC22D3 
forward 5’-GCTTGGTGTTACTAGGCCCC-3’, reverse 5’-AGGATAGAGCTTCAGGCA 
CAA-3’, Tsc22d3 forward 5’-ACAGAAGGCTGACTTGGCTC-3’, reverse 5’-GGCCAC 
GATGGCTAAGGAAT-3’. The annealing temperature for the PCR, run with the 5xHotFirePOl 
EvaGreen qPCR Mix under the program described in 2.6, was set at 64.4 °C.  
 
2.18.2 Sequencing analysis 
gDNA was extracted with QuickExtract® DNA Extraction Solution (#101094, Biozym, 
Hessisch Oldendorf, Germany). PCR of the edited region was performed as mentioned above, 
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the PCR products were purified and sent for analysis via Sanger sequencing. The sequencing 
primer sequences were: TSC22D3 5’-GCCACGATGGCTAAGGAATG-3’, Tsc22d3 5’-GAT 
AGAGCTTCAGGCACAATATAG-3’. Analysis of the sequencing files for indel detection was 
performed with assistance of the CRISP-ID web application (Dehairs et al., 2016), and the ICE 
analysis tool (Synthego, Redwood City, CA, USA). 
 
2.19 Serum Analysis 
Serum collected from young and aged mice was sent to the “Zentrallabor des 
Universitätsklinikums des Saarlandes” for clinical chemistry analysis. The determination of 
corticosterone and 11-dehydrocorticosterone (11-DHC) levels in serum was performed by the 
research group of Professor Markus Meyer (Centre for Molecular Signalling (PZMS), Saarland 
University), as described under 2.22. 
 
2.20 Thiobarbituric acid reactive substances (TBARS) assay 
Products of lipid peroxidation were measured in liver tissue from young and aged mice, 
following a previously described protocol (Simon et al., 2014). The total TBARS are expressed 
as µmol malondialdehyde (MDA) equivalents per µg of total protein, quantified using the 
Pierce™ BCA Protein Assay Kit. 
 
2.21 Determination of 11β-HSD1 activity in peritoneal macrophages 
The determination of 11β-HSD1 activity was performed by Rebecca Linnenberger and Dr. 
Jessica Hoppstädter. The activity of 11β-HSD1 in PMs from young and aged mice was 
measured incubating cells with 0.1 µM or 1 µM cortisone-D8 for 24 hours. At the end of 
treatment, supernatants were collected and analysed as described under 2.22 to measure 
cortisone-D8 and cortisol-D8 levels. The conversion to cortisol-D8 was expressed as percentage 
of the total steroid measured, and is presented per µg of total protein, quantified using the 
Pierce™ BCA Protein Assay Kit. 
 
2.22 Determination of steroid levels via LC-HRMS/MS 
The determination of steroid levels was performed by the research group of Professor Markus 
R. Meyer (Centre for Molecular Signalling (PZMS), Saarland University), using liquid 
chromatography–high resolution mass spectrometry (LC-HRMS/MS). Samples were mixed 1:1 
with an internal standard (cortisol-D4, 100 µg/ml in acetonitrile containing 0.1% formic acid), 
and centrifuged for 10 min at 18,407 x g and -10 °C. The supernatant was transferred into an 
MS vial and a volume of 5 µl was used for analysis. 
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Chromatographic separation of the analytes was carried out on a Dionex Ultimate UHPLC 
System (Thermo Fisher Scientific) using an AccucoreTM Phenyl Hexyl LC column (100 mm x 
2.1 mm, 2.6 µm) heated to 40 °C. Mobile phase A was water with 0.1% formic acid and 
ammonium formate, mobile phase B was acetonitrile with 0.1% formic acid. The LC gradient 
was as follows: starting with 2% solvent B over 0.1 min, the gradient was increased to 98% 
solvent B until 5 min, maintained at 98% until 7.5 min, and decreased to 2% until 10 min. The 
flow rate was set to 600 µl/min. Detection of analytes was achieved via high resolution mass 
spectrometry on a ThermoFisher Q-Exactive Plus equipped with a heated electrospray 
ionization (HESI)-II source. The HESI-II source conditions were as follows: sheath gas, 
nitrogen, at 55 arbitrary units; auxiliary gas, nitrogen, at 15 arbitrary units; temperature, 450 °C; 
spray voltage, 3.50 kV; ion transfer capillary temperature, 275 °C; and S-lens RF level, 55.0. 
Mass spectrometry was done in positive polarity mode using targeted single ion monitoring 
(tSIM) mode. The settings for tSIM mode were as follows: resolution, 35,000; microscans, 1; 
AGC target, 5e4; maximum IT, 200 ms; isolation window, 2.0 m/z; normalised collision energy 
(NCE), 35; scan range, m/z 150–900; spectrum data type, profile; and underfill ratio, 0.5%. The 
peak areas of the analytes were normalised using the internal standard peak area ratio. 
 
2.23 Statistics 
Results are expressed as mean ± SEM (standard error of the mean). Statistically significant 
differences between means were determined using the GraphPad Prism 6.0 or Origin 2019 
software. Unless stated otherwise, an unpaired Welch’s t-test was performed for the comparison 
of two groups, and the comparison of three or more groups was carried out by one or two-way 
analysis of variance (ANOVA) followed by Bonferroni’s post-hoc analysis for individual 
differences. Where specified, median comparison of two groups was performed using Mann 
Whitney U Test; and median comparison of three or more groups was carried out by Kruskal-
Wallis test followed by Dunn’s post-hoc analysis. Results were considered significant at 
P<0.05. 
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3. Chapter I  
 
The glucocorticoid-induced leucine zipper (GILZ) 
mediates statin-induced muscle damage 
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3.1 Introduction 
Statins are the first line of treatment in the management of hyperlipidaemia and prevention of 
CVD (Catapano et al., 2016; Grundy et al., 2018). These drugs are inhibitors of the HMG-CoA 
reductase enzyme, preventing the biosynthesis of cholesterol in the liver by blocking the 
mevalonate pathway and, as a consequence, enhancing clearance of circulating LDL-
cholesterol (Sirtori, 2014). Since their introduction in 1987, statin prescription rates have risen, 
as shown by several studies in different populations (Nolte et al., 2010; Salami et al., 2017; 
Vancheri et al., 2016), positioning them among the most prescribed drug classes worldwide. 
Given the high prevalence of CVD, and the favourable data on CVD prevention by 
statins (Heller et al., 2017; Taylor et al., 2013), this tendency seems to be maintained. 
 
Statins have a satisfactory safety profile, their most relevant adverse effect being skeletal 
muscle toxicity (Grundy et al., 2018). SAMS have an incidence of 5–29% in clinical practice 
(Grundy et al., 2018; Stroes et al., 2015), can range from mild myalgia to, in rare cases, fatal 
rhabdomyolysis (Moßhammer et al., 2014), and are a frequent cause for non-adherence to 
treatment or its discontinuation (Laufs et al., 2017). Although several studies have been 
conducted, and a number of risk factors that contribute to the onset of SAMS have been 
described, such as sex, pharmacokinetic differences, or genetic factors (Needham and 
Mastaglia, 2014; du Souich et al., 2017), the molecular mechanisms leading to myopathy are 
still not fully understood.  
 
GILZ was first described as a dexamethasone-induced, immunomodulatory protein (D’Adamio 
et al., 1997). Since then, it has been shown that GILZ  expression is not restricted to immune 
cells but is extended to several tissues and cell types, including skeletal muscle (Cannarile et 
al., 2001). GILZ plays multiple roles in both, glucocorticoid and non-glucocorticoid-mediated 
cellular processes (Ayroldi and Riccardi, 2009) beyond its immune-modulating function. For 
instance, studies demonstrated a role for GILZ in inhibition of adipocyte differentiation (Shi et 
al., 2003), in sodium homeostasis in the kidney, where it is robustly induced by aldosterone 
(Rashmi et al., 2017; Soundararajan et al., 2005), and in spermatogenesis, where lack of GILZ 
leads to hyperactivity of Ras signalling pathway and apoptosis during meiosis (Bruscoli et al., 
2012). Of particular interest is the role described for GILZ in the regulation of skeletal muscle 
differentiation: it was shown that GILZ is strongly induced after dexamethasone treatment. In 
this setting, GILZ mediated dexamethasone anti-myogenic action via inhibition of the 
transcriptional activity of an early myogenic regulatory factor (MRF), MyoD (Bruscoli et al., 
2010). 
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We analysed different publicly available gene expression profiling datasets that suggest statins 
were able to induce GILZ in different cell types (GEO accession numbers GDS2987, 
GSE32547, GSE4883). Interestingly, the analysis of a transcription profiling of human 
quadriceps femoris muscle following statin treatment suggested a moderate increase in GILZ 
expression in biopsies from patients receiving atorvastatin and simvastatin for 8 weeks, 
compared with those receiving placebo (ArrayExpress dataset E-TABM-116 (Laaksonen et al., 
2006), Figure 3.1). In the present study, we aimed to test the hypothesis that GILZ plays a role 
in the onset of SAMS, focusing on both, myotoxic and anti-myogenic effects. 
 
 
Figure 3.1. Analysis of the publicly available ArrayExpress dataset E-TABM-116: transcription profiling of 
human quadriceps femoris muscle following statin treatment. GILZ mean expression (NCBI RefSeq 
NM_004089.3; scan REFs GI_37622900-A, GI_37622900-I) is shown as fold of baseline. Connected data points 
represent patients before and after intervention. 
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3.2 Results 
3.2.1 Statins are toxic towards skeletal muscle cells 
We used the MTT assay to measure cell viability of C2C12 myoblasts and differentiating 
myotubes treated with increasing concentrations of atorvastatin, cerivastatin, simvastatin in its 
lactone and acid forms, and pravastatin, for 24 hours. All statins were toxic towards myoblasts, 
although higher concentrations of the hydrophilic statin pravastatin were needed to cause a 
significant decrease in cell viability (Figure 3.2 A). In myotubes, neither pravastatin nor 
simvastatin acid was significantly toxic at the evaluated concentrations (Figure 3.2 B). 
 
Figure 3.2. Statin cytotoxicity towards muscle cells. C2C12 myoblasts (A) or 48-hours myotubes (B) were treated 
with increasing concentrations of atorvastatin (Ator), cerivastatin (Ceri), pravastatin (Prav), simvastatin (Sim) acid 
or simvastatin lactone for 24 hours. The cell viability was measured via MTT assay. Data show the mean of three 
independent experiments performed in replicates ± SEM. **P < 0.01, ***P < 0.001 for the lowest concentration 
that caused a significant decrease in viability relative to the control. 
In accordance with the literature (Skottheim et al., 2008; Taha et al., 2016), comparison of the 
dose-response curves also showed that the lactone form of simvastatin was more toxic towards 
muscle cells than the active acid form of the drug [statin main effect, myoblasts F(1,24)=115.8, 
P<0.001; myotubes F(1,24)=21.16, P<0.001]. 
 
3.2.2 Non-toxic concentrations of statin induce GILZ in skeletal muscle cells 
To first evaluate whether GILZ expression was modified in muscle cells in the presence of 
statins, we treated C2C12 myoblasts with a non-toxic concentration of atorvastatin (3 µM) for 
up to 24 hours and measured the levels of Gilz mRNA at different time points. A significant 
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increase compared with the control was detected after 8 hours of treatment, to a level of 
induction that was maintained until the end of treatment (Figure 3.3). 
 
 
Figure 3.3. Effect of statin treatment on Gilz mRNA expression in C2C12. C2C12 myoblasts were treated with 
atorvastatin (3 µM) for up to 24 hours. Gilz expression was normalised against the housekeeping gene (Rn18s) 
and is presented as fold change of control. Data show the mean of 3 independent experiments performed in 
replicates ± SEM. *P<0.05, **P<0.01, relative to the control. 
3.2.3 Toxic concentrations of statin induce GILZ expression  
Next, we treated myoblasts and myotubes with 50 µM atorvastatin, simvastatin, or cerivastatin. 
At this concentration all statins were cytotoxic after 24 hours, but not at 6 hours (Figure 3.2 and 
data not shown). We detected an increase in Gilz mRNA expression after 6 hours of treatment 
with all statins, which was reversed by the addition of mevalonate (100 µM) to the medium, 
indicating that the mechanism of GILZ induction relates to the inhibition of HMG-CoA 
reductase (Figure 3.4 A–B). In myotubes, the increase in Gilz expression was modest compared 
with that of myoblasts. Western blot analysis showed an elevated expression of GILZ protein 
in both, C2C12 and primary murine myoblasts treated with toxic concentrations of statins 
(Figure 3.4 C–F). 
 
3.2.4 GILZ induction can be reversed by geranylgeranyl pyrophosphate 
The inhibition of HMG-CoA by statins not only impairs cholesterol biosynthesis, but also other 
biosynthetic pathways. Of main importance is the inhibition of protein prenylation resulting 
from decreased synthesis of the isoprenoid derivatives GGPP and FPP. Thus, we evaluated 
whether GILZ induction could be reversed by the addition of any, or both, of these mediators 
to the medium. Co-treatment of C2C12 myoblasts with 10 µM GGPP in addition to simvastatin 
completely reversed Gilz induction, while FPP had no effect (Figure 3.4 G). 
 
C o 2 4 8 1 6 2 4
0 .0
0 .5
1 .0
1 .5
t im e  (h )
G
il
z
 x
-f
o
ld
*
* * * *
Chapter I 
 
39 
 
Figure 3.4. Effect of statin treatment at toxic concentrations on GILZ expression in muscle cells. C2C12 myoblasts 
(A) or 72-hour myotubes (B) were treated with 50 µM statin in the absence or presence of mevalonate (MVA, 
100 µM) for 6 hours, Gilz mRNA expression was measured. GILZ protein expression was measured in C2C12 
(C) and primary murine (D) myoblasts after treatment with 50 µM statin for 6 hours. One representative blot is 
shown. Densitometric analysis, normalised to the housekeeping protein (E,F). C2C12 myoblasts were treated with 
50 µM simvastatin in the absence or presence of GGPP and FPP (10 µM) for 6 hours, Gilz mRNA levels were 
measured (G). mRNA expression was normalised against the housekeeping gene (Csnk2a2) and is presented as 
fold change of control. Data show the mean of at least 2 independent experiments performed in replicates ± SEM. 
**P<0.01, ***P<0.001 relative to the corresponding control, +++ P<0.001 relative to the non-MVA condition. 
3.2.5 Statin-induced impairment of myogenesis is accompanied by GILZ induction 
Myogenesis is a multistep, tightly regulated process that leads to the formation of skeletal 
muscle, both during embryonic development as well as in adult life, to maintain muscle 
homeostasis and repair muscle after injury (Bentzinger et al., 2012). Statins are not only toxic 
towards skeletal muscle fibres but might also impair the muscle regeneration process (Baba et 
al., 2008; Ogura et al., 2007; Trapani et al., 2012). To examine these effects, we induced 
differentiation of C2C12 myoblasts by switching confluent cell layers to differentiation medium 
(DM) in the absence or presence of statins, and evaluated myotube formation by Jenner-Giemsa 
staining and myosin heavy chain (MHC) immunofluorescence. We observed that treatment of 
C2C12 cells with sub-toxic concentrations of statins during differentiation resulted in less 
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myotube formation, and a significantly reduced fusion index after 6 days, where fully 
differentiated myotubes were visible in the control (Figure 3.5). 
 
 
Figure 3.5. Effect of statins on C2C12 differentiation. C2C12 were induced to differentiate for 6 days in the 
absence or presence of atorvastatin (5 µM), pravastatin (10 µM), cerivastatin (0.1 µM), and simvastatin (1 µM), 
and subjected to MHC IF (A, scale bar, 50 µm) or Jenner-Giemsa staining (C, scale bar, 100 µm). Representative 
images are shown. The degree of differentiation was quantified by measuring the fusion index in IF images (B), 
and myotube density in Jenner-Giemsa images (D). Correlation between the degree of Gilz mRNA induction after 
72 hours of statin stimulation (Figure 3.6 A) and fusion index (E). Data show the mean of 3 independent 
experiments performed in replicates ± SEM. *P<0.05, **P<0.01, ***P<0.001 relative to the control.  
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We analysed GILZ expression levels in differentiating C2C12 and primary murine myotubes 
treated with statins, finding that the impairment in myogenesis was also accompanied by GILZ 
induction on both, mRNA and protein level (Figure 3.6). Pearson correlation analysis showed 
a negative correlation between the fold increase in Gilz mRNA levels, and the fusion index 
(r2=0.8575). Since GILZ has been shown to mediate the anti-myogenic effects of 
dexamethasone (Bruscoli et al., 2010), we hypothesised that it might also be involved in the 
effects observed after statin treatment. 
 
 
Figure 3.6. Effect of statins on GILZ expression during myogenesis. C2C12 were induced to differentiate for 72 
hours in the absence or presence of atorvastatin (5 µM), pravastatin (10 µM), cerivastatin (0.1 µM), and simvastatin 
(1 µM). Gilz expression data was normalised against the housekeeping gene (Csnk2a2) and is presented as fold 
change of control (A). GILZ protein levels in C2C12 (B) and primary murine (C) myotubes treated with 
atorvastatin (5 µM) during myogenesis. Representative blots are shown. Data show the mean of 3 independent 
experiments ± SEM. *P<0.05; **P<0.01, ***P<0.001 relative to the control. 
3.2.6 GILZ knockout abolishes the cytotoxic effects of statins 
To assess whether loss of GILZ could rescue statin-induced cytotoxicity, we isolated primary 
myoblasts from WT and GILZ KO mice, treated them with increasing doses of statins, and 
measured cell viability after 24 hours. Comparison of the dose-response curves obtained 
showed significant differences between genotypes: GILZ KO myoblasts were significantly less 
sensitive towards atorvastatin, cerivastatin, and simvastatin treatment than their WT 
counterparts [cell type main effect F(1,124)=10.06, P=0.002; F(1,124)=26.24, P<0.0001; and 
F(1,116)=24.18, P<0.0001, respectively, Figure 3.7 A–C].  
 
Due to the importance of the PI3K/Akt signalling pathway in statin-induced 
myotoxicity (Bonifacio et al., 2015; Mallinson et al., 2009), we hypothesised that the resistance 
to cell death from GILZ KO myoblasts might be related to modulation of the Akt 
phosphorylation status. Indeed, atorvastatin treatment induced dephosphorylation of Akt and 
activated the apoptotic pathway, as observed by cleaved caspase-3 detection, in WT myoblasts. 
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On the other hand, Akt phosphorylation levels were restored to that of the control in statin-
treated GILZ KO cells, and the active form of caspase-3 was undetectable (Figure 3.7 D–E). 
 
 
Figure 3.7. Effect of GILZ knockout on statin-induced myotoxicity. WT and GILZ KO primary murine myoblasts 
were treated with atorvastatin (A), simvastatin (B) or cerivastatin (C) in increasing concentrations for 24 hours. 
The cell viability was measured via MTT assay and differences between curves were analysed by two-way 
ANOVA. Myoblasts were treated with atorvastatin (50 µM) for 6 hours, Akt phosphorylation and caspase-3 
activation were measured by western blot. One representative blot is shown (D). The ratio of phosphorylated to 
total Akt was measured by densitometric analysis and normalised to the corresponding control (E). Data show the 
mean of at least 3 independent experiments performed in replicates ± SEM. *P<0.05, **P<0.01, ***P<0.001 
relative to the control. 
As an ex vivo model for the evaluation of statin myotoxicity, we used flexor digitorum brevis 
myofibres isolated from WT and KO animals. These short fibres can be isolated, dissociated, 
and cultured, representing a more mature system for evaluation of statin effects than cell culture 
systems, since myoblasts in vitro can differentiate to myotubes but are unable to form fully 
differentiated myocytes and, therefore, do not exactly resemble the features of mature muscle 
(Ravenscroft et al., 2007; Sakamoto and Kimura, 2013). Treatment of FDB fibres from WT 
mice with atorvastatin, simvastatin, and cerivastatin induced vacuolation at 72 hours. After 5 
days the sarcomere structures were no longer visible, the fibres were swollen, ruptured, and 
blebs appeared (Figure 3.8 A and data not shown). Viability analysis using the trypan blue 
exclusion method after 5 days indicated that statins induced fibre death in a dose-dependent 
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manner. Loss of GILZ prevented the morphological changes indicative of myotoxicity and 
made the fibres resistant towards statins: in KO fibres, there were no significant differences in 
viability between the control and treatments at any of the concentrations evaluated (Figure 3.8 
A–B). 
 
 
Figure 3.8. Effect of GILZ knockout on statin-induced FDB myofibre toxicity. WT and GILZ KO FDB myofibres 
were treated with cerivastatin (1 µM) for up to 120 hours and imaged for morphological analysis, representative 
pictures are shown (A). Scale bar, 20 µm. Cell viability was measured after 120 h of treatment, using the trypan 
blue exclusion method (B). Data show the mean of 4 independent experiments performed in replicates ± SEM. 
*P<0.05, ***P<0.001 relative to the corresponding control. 
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3.2.7 GILZ contributes to statin-induced inhibition of myogenesis 
To investigate the contribution of GILZ to statin-induced inhibition of myogenesis, we 
differentiated WT and GILZ KO myoblasts in the presence of statins and evaluated the 
expression of the MRF myogenin, which is required in cells committed to the myogenic 
program for driving their fusion and terminal differentiation (Bentzinger et al., 2012). We 
observed a decrease in myogenin protein levels in WT primary murine myoblasts induced to 
differentiate for 72 hours in the presence of atorvastatin. By contrast, the expression of 
myogenin in atorvastatin treated GILZ KO cells was restored to that of the control (Figure 3.9), 
providing evidence that GILZ acts as a mediator of the anti-myogenic effects of statins. 
 
 
Figure 3.9. Effect of GILZ knockout on statin-induced anti-myogenic effects. Primary murine myoblasts from 
WT and GILZ KO animals were induced to differentiate for 72 hours in the absence or presence of atorvastatin 
(5 µM). Myogenin levels were measured via western blot, one representative blot is shown (A). Densitometric 
analysis (B). Data show the mean of 3 independent experiments ± SEM. **P<0.01 relative to the control. 
To further analyse the role of GILZ in these effects, we generated C2C12 cell lines stably 
expressing scrambled or GILZ shRNA constructs by lentiviral transduction. The C2C12shGilz1 
and C2C12shGilz2 cell lines showed a degree of gene knockdown of approximately 70% and 
60%, respectively, whereas in the scrambled control cell line, C2C12scr, Gilz expression was 
unaffected (Figure 3.10).  
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Figure 3.10. Gilz expression in stable C2C12shGilz cell lines. Scrambled and shGILZ-silenced C2C12 cell lines 
were generated by lentiviral transduction, Gilz mRNA expression was normalised against the housekeeping gene 
(Csnk2a2) and is presented as fold change of the control. Data show the mean of 3 independent experiments ± 
SEM. **P<0.01 relative to scrambled cells.  
We hypothesised that, as a result of restored myogenin expression, Gilz silencing should 
reinstate the ability of the myoblasts to differentiate in the presence of statins. Importantly, we 
found that C2C12shGilz1 and C2C12shGilz2 cells displayed terminally differentiated myotubes 
already after 4 days in DM, whereas C2C12scr cells were not fully differentiated yet (Figures 
3.11 A and 3.12 A, upper panels). GILZ knockdown, however, could only partially reverse the 
impairment in differentiation caused by statins: although Jenner-Giemsa staining showed 
myotube formation in the C2C12shGilz lines (Figure 3.12, lower panels), these cells were not 
differentiated to the same extent as their controls. Nevertheless, fusion index analysis of MHC-
stained cells showed an improvement in myotube formation from C2C12shGilz cells compared 
with the C2C12scr line (Figure 3.11 B). 
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Figure 3.11. Effect of GILZ absence on statin-induced anti-myogenic effects, as measured by MHC IF. Scrambled 
(Scr)- and shGILZ-C2C12 cell lines were induced to differentiate for 4 days in the absence or presence of 
atorvastatin (5 µM), cerivastatin (0.1 µM), or simvastatin (1 µM), and subjected to MHC IF, representative images 
are shown (A). Scale bar, 50 µm. The degree of differentiation was quantified by measuring the fusion index (B) 
and is presented relative to the controls. Bars show the mean of at least 3 independent experiments performed in 
replicates ± SEM, data points correspond to each quantified field. Comparison was performed using Kruskal-
Wallis test followed by Dunn’s post-hoc analysis. *P<0.05. 
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Figure 3.12. Effect of GILZ absence on statin-induced anti-myogenic effects, as measured by Jenner-Giemsa 
staining. Scrambled (Scr)- and shGILZ-C2C12 cell lines were induced to differentiate for 4 days in the absence or 
presence of atorvastatin (5µM), cerivastatin (0.1 µM), or simvastatin (1 µM), and subjected to Jenner-Giemsa 
staining, representative images are shown (A). Scale bar, 100 µm. The degree of differentiation was quantified by 
measuring the myotube density and is presented as fold of the corresponding controls (B). Bars show the mean of 
at least 3 independent experiments performed in replicates ± SEM, data points correspond to each quantified field.  
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3.2.8 FoxO3 mediates GILZ induction by statins in muscle 
In the search for potential upstream regulators of GILZ expression after statin treatment in 
muscle, we focused on the Forkhead Box O3 (FoxO3) protein. FoxO3 is a direct 
phosphorylation target of Akt, and our observations in skeletal muscle tissue from FoxO3 KO 
mice, where Gilz expression levels were significantly lower than in WT animals, hinted towards 
FoxO3 as a transcriptional regulator of GILZ in this tissue (Figure 3.13 A). Like in primary 
myoblasts, we observed that treatment of C2C12 myoblasts with statins led to Akt 
dephosphorylation and, in line with this, to reduced levels of phosphorylated FoxO3 protein, in 
parallel to GILZ induction (Figure 3.13 B–D). Hence, we performed chromatin 
immunoprecipitation to evaluate whether FoxO3 activated Gilz transcription in myoblasts by 
binding to the forkhead responsive elements (FHRE) in its promoter following statin treatment. 
Indeed, we found sequences corresponding to three of the four FHRE present in the Gilz 
promoter in immunoprecipitates from atorvastatin-treated myoblasts, indicating that GILZ 
induction in muscle follows dephosphorylation, nuclear translocation, and activation of FoxO3 
(Figure 3.13 E).  
 
3.2.9 Statins induce Gilz in zebrafish embryos, and deregulation of Gilz expression 
impairs somitogenesis 
The zebrafish is a powerful and versatile in vivo model for the study of developmental and 
physiological processes that has been used for the elucidation of statin effects on muscle 
development (Campos et al., 2016) and homeostasis (Hanai et al., 2007; Huang et al., 2011; 
Pasha and Moon, 2017). Given that the zebrafish expresses a GILZ orthologue (Tse et al., 
2013), we chose it as an in vivo model to study the effects of statins on GILZ expression. 
 
In line with our in vitro findings, treatment of zebrafish embryos at 20 hpf with statins at 
concentrations that have been described to cause major muscle damage, led to an up-regulation 
of gilz mRNA (Figure 3.14 A). To characterise the effects of increased Gilz expression in 
zebrafish muscle development, we performed myosin IF in Gilz overexpressing embryos. 
Compared with control animals, we found a diffuse MHC staining with loss of septa, a clear 
sign that Gilz impairs embryonic muscle development. To causally link Gilz expression with 
statin-induced muscle damage, we considered performing gene silencing via MO injection to 
evaluate the effects of statin treatment in WT vs morphant embryos. gilz morphants, however, 
showed similar features to that of the overexpressing embryos in muscle, as observed by myosin 
staining (Figure 3.14 B), indicating that Gilz plays an important role in the regulation of 
somitogenesis. 
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Figure 3.13. Involvement of FoxO3 in statin-induced GILZ expression. Gilz expression on skeletal muscle from 
FoxO3 KO mice (A). mRNA expression data was obtained from WT and KO mice (n=5), normalised against the 
housekeeping gene (Csnk2a2), and is presented as fold change of WT in box-plots showing the 25–75th percentiles, 
mean (square), median (line) and range (whiskers). Western blot analysis C2C12 myoblasts treated with 50 µM 
statin for 6 hours, a representative blot is shown (B). Densitometric analysis of ratio of phosphorylated to total 
FoxO3 (C). ChIP analysis was used to detect the binding of FoxO3 to the Gilz promoter region (D). Expression 
data is presented as fold enrichment over IgG. Data show the mean of 3 independent experiments ± SEM. *P<0.05; 
**P<0.01, ***P<0.001 relative to the control. 
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Figure 3.14. Effect of statins on gene expression in zebrafish, and effect of gilz deregulation in zebrafish muscle 
development. Zebrafish embryos at 20 hpf were treated with cerivastatin or simvastatin lactone (1 µM) for 12 
hours (A). mRNA expression was normalised against the housekeeping gene (actb2) and is presented as fold 
change of control. MHC IF of gilz-overexpressing and gilz-morphant zebrafish embryos at 24 hpf, representative 
pictures are shown (B). Panels are side views, anterior, left. White dotted lines in Co outline the V-shape pattern 
of somites. Bar, 40 µm. Data show the mean of 3 independent experiments performed in replicates ± SEM. 
*P<0.05, **P<0.01, relative to the control. 
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3.3 Discussion 
More than 30 years after their introduction to the market, statins remain the cornerstone of the 
pharmacological management of hyperlipidaemia and CVD prevention. In light of their 
importance and extended use, the understanding of the mechanisms underlying the onset of 
SAMS is of highest relevance (Stroes et al., 2015). In the present study, we report a role for 
GILZ as a pivotal mediator of the myotoxic and anti-myogenic effects of statins. We first 
demonstrate that treatment of murine myoblasts with different statins, at concentrations typical 
for in vitro studies on SAMS (Bouitbir et al., 2012; Hanai et al., 2007; Schirris et al., 2015), 
induces GILZ expression. Since SAMS are a class effect, and several of the mechanisms 
underlying muscle toxicity are directly related to the inhibition of HMG-CoA (Osaki et al., 
2015; Trapani et al., 2012), we evaluated whether GILZ expression depended on this pathway 
as well. Indeed, we found GILZ induction to be mevalonate-dependent, more specifically, on 
geranylgeranylation.  
 
The significantly lower myotoxicity of the hydrophilic statin pravastatin (Gadbut et al., 1995; 
Kaufmann et al., 2006; Kobayashi et al., 2008; Schirris et al., 2015), might be the result of 
reduced cellular uptake in our in vitro setting, that also accounts for the rather modest levels of 
Gilz induction observed in comparison to the other statins. The hydrophilicity of the molecules 
is also of relevance when comparing the cytotoxic effects of the lactone vs hydroxy acid forms 
of statins towards muscle, given that the former are significantly more lipophilic than the latter 
(Skottheim et al., 2008). It has been reported that patients with atorvastatin-induced myopathy 
have increased levels of the lactone form of the drug in plasma (Hermann et al., 2006), and in 
vitro studies also demonstrated that physiological conditions that favour the conversion of 
statins to their lactone form, such as acidosis, increase statin myotoxicity (Taha et al., 2016).  
 
Several molecular mechanisms of statin-induced myotoxicity have been proposed, describing 
their deleterious effects on mitochondrial function, calcium homeostasis, and cell survival in 
the myocyte (du Souich et al., 2017). In our hands, statins caused Akt dephosphorylation and 
activation of the apoptotic cascade in undifferentiated myoblasts. This effect agrees with 
previous findings in cultured myotubes (Bonifacio et al., 2015; Johnson et al., 2004). Our 
observations suggest a crucial role for GILZ in mediating this action. First described in 
thymocytes as an anti-apoptotic protein (D’Adamio et al., 1997), GILZ can exert anti- or pro-
apoptotic effects depending on the cell type: for instance, GILZ has been shown to promote 
apoptosis through Mcl-1 downregulation in neutrophils (Espinasse et al., 2016), or by inhibition 
of the Akt/mTOR signalling pathway, in myeloma cells (Joha et al., 2012).  
 
There are discrepancies, however, in the mechanism by which statins induce cell death in 
cultured myoblasts/myotubes vs mature fibres. For instance, statins trigger apoptosis in cultured 
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cells, whereas mature skeletal muscles show necrotic features (Sakamoto and Kimura, 2013). 
Hence, instead of using terminally differentiated cultured myotubes, we chose isolated FDB 
myofibers as an ex vivo model to evaluate the effects of the absence of GILZ in statin toxicity 
towards mature muscle. We noticed that treatment of murine FDB fibres with atorvastatin, 
simvastatin, and cerivastatin caused cell death with similar features as those previously 
described for fluvastatin-treated rat FDB fibres (Sakamoto et al., 2011). Furthermore, in 
accordance with our observations in proliferating myoblasts, GILZ was of crucial importance 
in mediating statin-induced fibre breakdown. 
 
FoxO3 is a transcription factor involved in different aspects of muscle homeostasis, like 
regulation of mitochondrial metabolism, activation of protein breakdown via the ubiquitin-
proteasome and autophagy pathways, and inhibition of muscle precursor cell 
proliferation (Sanchez et al., 2014). In statin-induced myopathy, reports have shown that 
FoxO3 activation results in expression of the muscle atrophy-related protein MAFbx/atrogin-1 
and other genes implicated in muscle proteolysis in vitro and in vivo (Hanai et al., 2007; 
Mallinson et al., 2009). Moreover, FoxO3 has been reported as a transcriptional regulator of 
GILZ in T cells, where it drives IL-2 withdrawal-induced GILZ expression (Asselin-Labat et 
al., 2005). We found statin-induced GILZ expression in muscle to be FoxO3-dependent and, as 
mentioned above, GGPP dependent. These results are in accordance with previous studies that 
linked SAMS to reduced geranylgeranylation, but not farnesylation, of different small GTPases 
like Rac1, Rap1, and Rab1 (Baba et al., 2008; Cao et al., 2009; Johnson et al., 2004; Sakamoto 
et al., 2007). Our findings suggest that the inhibition of protein geranylgeranylation by statins 
downregulates the Akt signalling pathway, leading to FoxO3-driven GILZ induction, which in 
turn further decreases Akt phosphorylation and promotes apoptosis.  
 
The fact that GILZ is expressed in skeletal muscle, as observed by us and reported in earlier 
studies (Cannarile et al., 2001), might denote a role in muscle tissue homeostasis. Indeed, an 
earlier study showed that GILZ and its longer isoform, L-GILZ, modulate myogenesis in the 
absence of pharmacological intervention, and mediate glucocorticoid-induced inhibition of 
myogenesis by decreasing MyoD-mediated myogenin transcription, thus impairing myoblast 
fusion (Bruscoli et al., 2010). For this reason, we investigated the role of GILZ in the anti-
myogenic effects of statins. We found that all statins were able to induce GILZ transcription, 
an effect that seemed to correlate with the anti-myogenic effect of the statin used. A previous 
study reported no differences in myogenin mRNA levels in simvastatin-treated C2C12 (Baba 
et al., 2008). We, however, found myogenin protein expression to be impaired in primary 
differentiating myoblasts treated with atorvastatin. Moreover, our results in GILZ KO 
myoblasts indicate that statin-induced GILZ expression, and the consequent myogenin 
transcriptional repression, is a mechanism by which this class of drugs impairs myogenesis. 
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GILZ silencing by shRNA caused the resulting C2C12shGilz cell lines to differentiate 
considerably faster than the C2C12scr control, even to a higher degree than observed for WT 
cells after terminal differentiation. This supports the importance of GILZ itself as a modulator 
of myogenesis and corresponds to our observations in zebrafish embryos, where Gilz 
overexpression severely impaired somitogenesis. Importantly, zebrafish embryos represent a 
frequently used in vivo model for the mechanistic study of SAMS (Campos et al., 2016, 2015; 
Huang et al., 2011; Pasha and Moon, 2017). The regulatory role played by Gilz in zebrafish 
embryonic development is rather complex: the study that first described the presence of a GILZ 
orthologue in zebrafish, showed that manipulation of Gilz expression in this model, either via 
MO silencing or mRNA overexpression, causes significant defects in embryonic development, 
altering the dorsoventral patterning, segmentation, and brain development processes (Tse et al., 
2013). In rodents, however, GILZ-independent regulatory pathways are most likely involved in 
the modulation of skeletal muscle development, since GILZ KO mice do not exhibit altered 
muscle features (unpublished observations). 
 
Even though myogenin expression was rescued in the absence of GILZ, we could not observe 
a complete recovery in myotube formation after statin treatment in C2C12shGilz cells. This might 
be related to residual GILZ expression in the silenced cells, or to additional pathways that 
mediate the anti-myogenic effects observed, such as the IGF-1/PI3K/Akt pathway (Ogura et 
al., 2007). Our observations indicate that GILZ is critical for statin-induced inhibition of 
myogenin, an MRF crucial for myoblast fusion and terminal differentiation (Asfour et al., 
2018). Additional factors, however, may also contribute to the inhibition of muscle regeneration 
by statins.  
 
Taken together, our data point towards GILZ as an essential mediator of the molecular 
mechanisms leading to statin-induced muscle damage and impairment of muscle regeneration. 
This study contributes to a better understanding of the molecular mechanisms underlying statin-
induced myopathy, a necessary step towards the development of prevention strategies and safer 
therapy approaches for a class of drugs that remains a pillar in the treatment of cardiovascular 
disease. 
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4. Chapter II 
 
A potential role for GILZ in the pleiotropic effects 
of statins 
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4.1 Introduction 
Statin therapy improves adverse outcomes in CVD patients (Almeida and Budoff, 2019), and 
is beneficial in primary prevention of CVD (Taylor et al., 2013). It has been suggested that the 
overall benefit of statin use is attributable not only to reduction of LDL-cholesterol but also to 
a plethora of pleiotropic effects, exerted on different cell types involved in cardiovascular 
homeostasis (Oesterle et al., 2017). Although the clinical significance of these effects is still 
debated (Labos et al., 2018), it is clear that statins reduce systemic inflammation, as 
demonstrated by different trials where reductions in high-sensitivity CRP are observed in 
patients with or without concomitant hyperlipidaemia (Ridker et al., 2008). 
 
Atherosclerosis, the main pathophysiological condition driving CVD, is considered a chronic 
inflammatory disease (Mendis et al., 2011; Tousoulis et al., 2014). Indeed, the key role of 
inflammation in this pathology could be confirmed with the results from the CANTOS trial, 
where therapeutic targeting of the pro-inflammatory cytokine IL-1β with canakinumab led to a 
significantly lower rate of recurrent cardiovascular events (Ridker et al., 2017). Development 
of the atherosclerotic plaque involves endothelial dysfunction, monocyte and T-cell recruitment 
and activation, lipid accumulation, and smooth muscle cell proliferation (Novikova et al., 2018; 
Ross, 1999). Statins have shown different beneficial, anti-inflammatory effects in these cell 
types: for example, reduction in expression of adhesion molecules in endothelial and smooth 
muscle cells (Chung et al., 2002), in matrix metalloproteinase (MMPs) secretion in 
macrophages and smooth muscle cells (Luan et al., 2003), or reduced inflammasome activation 
in endothelial cells (Wang et al., 2017). These effects are attributed to inhibition of Rho 
GTPase-mediated pro-inflammatory activity, of oxidative stress, and the activity of pro-
inflammatory transcription factors, like NF-кB (Huacuja Álvarez et al., 2006; Oesterle et al., 
2017; Tousoulis et al., 2014). 
 
GILZ is an immunomodulatory, anti-inflammatory protein (Ronchetti et al., 2015). Altered 
endogenous GILZ expression has been reported in different inflammation-related conditions, 
like obesity (Lee et al., 2016; Robert et al., 2016), rheumatoid arthritis (Beaulieu et al., 2010), 
endotoxin tolerance (Hoppstädter et al., 2015) and, interestingly, vascular inflammation (Hahn 
et al., 2014). Studies in different cell types indicate that GILZ exerts its anti-inflammatory 
activity via inhibition of NF-кB transcriptional activity (Ayroldi et al., 2001; Cheng et al., 2013; 
Yang et al., 2008). Of notice, apart from glucocorticoids, GILZ can be induced in response to 
other anti-inflammatory compounds like curcumin in macrophages (Hoppstädter et al., 2016), 
as well as by vascular protective conditions, such as laminar shear stress in endothelial cells 
(Hahn et al., 2014). We aimed at evaluating the hypothesis that statins can induce GILZ in two 
cell types involved in vascular inflammation, i.e. endothelial cells and macrophages, and that 
this protein plays a role in the anti-inflammatory, pleiotropic effects of statins. 
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4.2 Results 
4.2.1 Statin cytotoxicity towards endothelial cells and macrophages 
Evaluation of statin toxicity towards endothelial cells and macrophages was performed by 
treatment of HUVECs and BMMs with increasing concentrations of atorvastatin, cerivastatin, 
simvastatin in lactone and acid form, and pravastatin. The effects on cell viability were 
measured via MTT assay. Similar to the findings in skeletal muscle (Chapter I), pravastatin was 
the least toxic of statins, while the other statins were toxic already at low concentrations (Figure 
4.1). For this reason, concentrations in the nanomolar–low micromolar range were used for 
further experiments. The viability of BMMs was not affected by statin treatment at the 
evaluated concentrations (data not shown). 
 
 
Figure 4.1. Statin cytotoxicity towards endothelial cells. HUVEC were treated with atorvastatin, cerivastatin, 
pravastatin, simvastatin lactone or simvastatin sodium salt in increasing concentrations for 24 hours. The cell 
viability was measured via MTT assay. Data show the mean of three independent experiments ± SEM. *P<0.05, 
**P<0.01, ***P <0.001 for the lowest concentration that caused a significant decrease in viability relative to the 
control. 
4.2.2 Atorvastatin induces GILZ expression in endothelial cells and macrophages 
To assess the effects of statin treatment on GILZ expression in endothelial cells and 
macrophages, HUVECs and BMMs were treated with a non-toxic concentration of atorvastatin 
(3 µM) for up to 24 hours, to measure the levels of GILZ mRNA at different time points. 
Atorvastatin induced GILZ expression in endothelial cells already at 2 hours of treatment, the 
induction was significant at 8 hours and continued to increase until the end of treatment (Figure 
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4.2 A). Furthermore, a moderate increase in Gilz expression was observed in BMMs, 
statistically significant at 16 hours (Figure 4.2 D). The shear stress-inducible, atheroprotective 
transcription factor KLF2, is known to be upregulated by statins (Parmar et al., 2005; Tuomisto 
et al., 2008), and endothelial nitric oxide synthase (eNOS) is one of the key targets of statins in 
vascular endothelium (Margaritis et al., 2014); both mRNAs were also measured as positive 
controls. As expected, atorvastatin treatment induced KLF2 and eNOS expression in a time-
dependent manner (Figure 4.2 B–C, E). 
 
Figure 4.2. Effect of statin treatment on mRNA expression in endothelial cells and macrophages. HUVECs (A–
C) and BMMs (D–E) were treated with atorvastatin (3 µM) for up to 24 hours, mRNA expression levels were 
measured. Gene expression was normalised against the housekeeping gene (A–C ACTB; D–E Rn18s) and is 
presented as fold change of control.  Data show the mean of 3 independent experiments performed in replicates 
with cells derived from different donors ± SEM. *P<0.05, **P<0.01, ***P<0.001 relative to the control. 
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4.2.3 Statin-induced GILZ expression in HUVECs is mevalonate-dependent 
To evaluate the dependence of GILZ induction on HMG-CoA inhibition, HUVECs were treated 
with non-toxic concentrations of statins in the absence or presence of mevalonate. As shown in 
Figure 4.3, all statins induced GILZ expression after 24 hours of treatment. The effect was 
reversed by coincubation with mevalonate. 
 
 
Figure 4.3. Effect of mevalonate on statin-induced GILZ expression in endothelial cells. HUVECs were treated 
with atorvastatin (1 µM), pravastatin (50 µM), cerivastatin (100 nM), or simvastatin (200 nM) in the absence or 
presence of mevalonate (100 µM) for 24 hours. GILZ expression was normalised against the housekeeping gene 
(ACTB) and is presented as fold change of control.  Data show the mean of 2 independent experiments performed 
in replicates with cells derived from different donors ± SEM. *P<0.05, **P<0.01, ***P<0.001 relative to the 
control. + P<0.05 +++ P<0.001 relative to the non-MVA condition 
4.2.4 KLF2 is not involved in the regulation of GILZ expression in endothelial cells 
Given the main role played by KLF2 as mediator of the cardiovascular beneficial effects of 
statins, and the parallel upregulation of both genes observed upon atorvastatin treatment, it was 
of interest to evaluate whether regulation of KLF2 expression influenced GILZ expression in 
endothelial cells. The notion of KLF2 as transcriptional activator of GILZ expression was 
supported by in silico analysis of the murine Gilz promoter, where KLF2-binding sites were 
found (data not shown). Knockdown of the KLF2 gene in HUVECs was performed using an 
siRNA approach. In addition, overexpression was achieved by means of a doxycycline-
inducible lentiviral expression system. siRNA knockdown resulted in a 50% decrease in gene 
expression (Figure 4.4 A) but had no effects on baseline expression of GILZ in transfected 
HUVECs, compared with the scramble controls (Figure 4.4 B). Similarly, lentiviral 
overexpression at two different MOIs resulted in a 10–15-fold induction of KLF2 expression 
but had no effects on GILZ (Figure 4.4 C).  
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Figure 4.4. Effect of KLF2 knockdown and overexpression on GILZ expression in endothelial cells. HUVECs 
were transfected with siRNA targeting KLF2 at different concentrations for 24 hours, KLF2 levels were determined 
(A). GILZ levels were measured at the concentrations where significant KD was found (B). HUVECs were 
transduced with hKLF2 lentivirus and allowed to overexpress KLF2 for 72 hours before harvesting for mRNA 
analysis (C). mRNA expression was normalised against the housekeeping gene (ACTB) and is presented as fold 
change of control. Data show the mean of 3 independent experiments performed in replicates with cells derived 
from different donors (A–B) or a single experiment performed in duplicate (C) ± SEM. *P<0.05 relative to the 
control. 
4.2.5 Development of a GILZ-KO endothelial cell line model via CRISPR/Cas9 editing 
For analysis of the functional implications of GILZ induction by statins in vascular 
endothelium, a cell model with GILZ loss of function would be of interest. To this end, 
CRISPR/Cas9 technology, a highly versatile and efficient tool for gene editing (Boettcher and 
McManus, 2015), was used for the establishment of an endothelial GILZ-KO cell line. 
HUVECs are primary cells, hence not suitable for stable cell line generation. Therefore, the 
human dermal microvascular endothelium cell line HMEC-1 was chosen for CRISPR/Cas9 
mediated GILZ deletion. Statin treatment significantly induced GILZ expression in these cells 
to a similar extent as in primary cells (Figure 4.5). To avoid the caveats of plasmid cloning, 
transfection/transduction, and expression of the CRISPR components in the cells, a system that 
involved direct delivery of Cas9 recombinant protein and the synthetic sgRNA was chosen. The 
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gene editing experiment was also performed in C2C12 myoblasts and murine RAW 264.7 
macrophages, in parallel to HMEC-1 cells.  
 
 
Figure 4.5. Effect of statin treatment on GILZ expression in an endothelial cell line. HMEC-1 cells were treated 
with simvastatin or atorvastatin at 1 µM for 24 hours, GILZ mRNA expression was normalised against the 
housekeeping gene (ACTB) and is presented as fold change of control. Data show the mean of 2 independent 
experiments performed in replicates ± SEM. ***P<0.001 relative to the control. 
The GILZ gene is located on the X chromosome. For HMEC-1 and RAW264.7 cells, lines of 
male origin, this means only one allele needs to be edited by non-homologous end joining 
(NHEJ). C2C12, on the other side, is a female cell line with a hypo tetraploid karyotype —
including 4 copies of the X chromosome— (Casas-Delucchi et al., 2011), which makes it 
difficult to obtain a clone with complete knockout. The validated murine and human sgRNA 
sequences were located in the last exon of their corresponding gene (Figure 4.6 A-B). Off-target 
analysis performed with the GT-scan software tool (O’Brien and Bailey, 2014) showed no 
predicted off-target effects in exonic regions of the genomes, thus, specific editing could be 
expected. The T7E1 mismatch assay performed in the bulked cell population after transfection 
indicated cutting by Cas9 in C2C12 and HMEC-1, but not in RAW 264.7 (Figure 4.6 C). After 
clonal expansion, none of the 20 C2C12 clones screened had indels in all alleles, while the 3 
HMEC-1 clones that survived showed successful genomic 1 and 34-bp deletions (Figure 4.7). 
The growth of these clones, however, was impaired. For this reason, the cells could not be 
further expanded for characterization. As for the RAW264.7 macrophage model, the lack of 
editing could be due to poor transfection efficiency, common for this cell line. Hence, to 
facilitate the screening for functional sgRNAs and the generation of KO cell lines, a Cas9-
expressing cell line was developed by a lentiviral approach (data not shown). 
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Figure 4.6. CRISPR/Cas9 – mediated GILZ knockout in cell lines. Schematic representation of the human (A) 
and murine (B) GILZ genes, black arrows indicate the approximate position of the sgRNAs. Genome editing 
efficiency in bulked population of edited RAW 264.7, C2C12, and HMEC-1 cells (C). The target genomic region 
from control and transfected cells was amplified by PCR and subjected to mismatch T7E1 assay, products were 
separated on an agarose gel for analysis. Cleavage efficiency was estimated from the intensities of the parental and 
cleaved bands. 
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Figure 4.7. Validation of CRISPR/Cas9-mediated genome editing in HMEC-1 and C2C12 clones via Sanger 
sequencing. Sequence of three edited HMEC-1 clones was obtained, chromatogram analysis shows a single allele 
sequence. Clones 1 and 5 have the same 1 bp deletion (A) clone 2 has a 34 bp deletion (B). Example sequence of 
a non-pan-allelic edit obtained in C2C12 clone 17, two sequences are observed in the chromatogram, one 
corresponding to the WT sequence, and one with a 4 bp deletion (C). Sequences were deconvoluted using the 
CRISP-ID web application, first rows correspond to the reference, WT cells, and bottom rows to the observed 
sequencing results. 
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4.3 Discussion 
The benefits of statin treatment on CVD are indisputable. Nevertheless, further study of the 
molecular mechanisms underlying the actions of statins in vascular inflammation are still 
needed (Almeida and Budoff, 2019). Here it is demonstrated that statins induce the anti-
inflammatory protein GILZ in two cell types of critical importance in atherogenesis (Novikova 
et al., 2018), i.e. endothelial cells and macrophages. The induction was mevalonate-dependent, 
that is, specific to their mechanism of action. Based on the results in muscle cells (chapter I), it 
might be possible that statin-induced GILZ expression occurs via inhibition of protein 
prenylation in these cell types as well. The role of GILZ in inflammation has been characterised 
in different tissues and cell types, and more recently it has been shown that GILZ peptide 
analogues have therapeutic potential for treatment of chronic inflammatory diseases in the 
central nervous system (Gu et al., 2018; Srinivasan et al., 2016). Therefore, one might expect 
GILZ induction to be at least partially responsible for the pharmacological effects of statins in 
vascular inflammation.  
 
A well-recognised mediator of the pleiotropic effects of statins is KLF2 (Parmar et al., 2005; 
Sen-Banerjee et al., 2005; Tuomisto et al., 2008), a transcription factor that can also be induced 
by glucocorticoid receptor activation in macrophages, in what has been proposed to be an 
important cooperation for the control of inflammatory processes (Chinenov et al., 2014). 
Although the induction patterns of KLF2 and GILZ after atorvastatin treatment were very 
similar in HUVECs, the exploratory findings presented here do not support the hypothesis that 
KLF2 acts as an upstream regulator of GILZ expression in endothelium. Whether GILZ might 
act as an upstream regulator of KLF-2 expression remains to be investigated. 
 
It was possible to successfully introduce genomic edits in the GILZ gene in HMEC-1 cells by 
using CRISPR/Cas9 technology, establishing a protocol for generation of knockouts in our 
laboratory that can be of use to evaluate the functional aspects of GILZ induction by statins. 
The three HMEC-1 clones with validated deletions exhibited impaired growth, which might be 
indicative of a role for GILZ in endothelial cell proliferation. Since the validated target sgRNA 
sequence was in the last exon of the gene, constitutive to all transcript variants but at the C-
terminal portion of the protein, it is likely that the clones did not have abolished expression of 
GILZ. For CRISPR/Cas9 mediated KO generation it is recommended targeting portions near 
the N-terminus of the protein, or 5’ constitutive exons, to increase the probability of a frameshift 
mutation that leads to nonsense-mediated mRNA decay or a non-functional protein product 
(Doench et al., 2014; Joung et al., 2017). The deletions obtained here, however, may cause 
alterations in the C-terminal portion of GILZ, responsible for interaction with NF-кB (Di Marco 
et al., 2007). Further work in generation of GILZ KO HMEC-1 cells might clarify this issue.  
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Although still a matter of discussion, a body of evidence points towards pleiotropic effects of 
statins as major contributors to their beneficial effects on the cardiovascular system. The 
findings presented in this study open the opportunity to investigate the potential role of GILZ 
as mediator of the anti-inflammatory actions of statins in the cardiovascular system.
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5. Chapter III 
 
Macroph-aging: role of glucocorticoid metabolism 
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5.1 Introduction 
Aging is characterised by a gradual decline of the immune function that results in a chronic, 
low-grade systemic inflammatory state, termed “Inflammaging” (Franceschi et al., 2000). This 
chronic inflammation, fuelled by continuous exposure to a number of exogenous and 
endogenous antigens during lifespan, is considered by geroscience one of the seven pillars of 
aging, and largely determines the onset of age-related diseases (Franceschi et al., 2018).  
 
Different factors, like cell senescence, endocrine, and metabolic alterations, contribute to 
sustain inflammaging (Bandaranayake and Shaw, 2016). Among these, the macrophage is 
considered a key cell type driving age-related inflammation. Indeed, since its origins, the theory 
of inflammaging has been intertwined with “macroph-aging”, that is, the chronic activation of 
macrophages with age (Franceschi et al., 2000; Prattichizzo et al., 2016). Macrophages are a 
widely distributed, heterogeneous, plastic cell population, with central roles as effector and 
mediator of the innate and adaptive immune response (Janeway et al., 2001; Wynn et al., 2013). 
Several studies in humans and animals have reported age-related alterations in different 
macrophage functions, such as phagocytic activity, pro-inflammatory cytokine secretion, and 
antigen presentation (Jackaman et al., 2017; Sebastián et al., 2005). Furthermore, loss of 
macrophages has been associated with improved inflammatory-induced pathology and survival 
after systemic immunostimulation (Bouchlaka et al., 2013), and with reduced 
neurodegeneration (Yuan et al., 2018) in murine models of aging. 
 
Endogenous GCs are main regulators of the immune function (Cain and Cidlowski, 2017). GC 
secretion is regulated in a circadian manner, and in response to stress, by the HPA axis, the 
function of which is dysregulated with advancing age (Gupta and Morley, 2014). Although 
sometimes contradictory, literature reports regarding altered cortisol secretory profiles in 
humans often describe elevations in cortisol levels in aged subjects that correlate with negative 
health outcomes (Gaffey et al., 2016). Noticeably, increased cortisol levels seem to be a 
phenotypic feature of centenarians, subjects who are able to cope with inflammation and have 
achieved longevity by mounting an effective anti-inflammaging response (Franceschi et al., 
2007; Genedani et al., 2008; Sergio, 2008). Thus, the balance between pro- and anti-
inflammatory mediators is what ultimately determines successful aging. Because of their role 
in modulation of the inflammatory response (Busillo and Cidlowski, 2013), one might 
hypothesise that alterations in GC metabolism affect the function of immune cells, including 
macrophages, during aging. 
 
Previous work in our group found a pro-inflammatory phenotype in aged (85 weeks) C57BL/6 
mice compared with their young (10 weeks) counterparts. This phenotype was characterised by 
higher levels of circulating pro-inflammatory cytokines, like TNF-α, and lower levels of total 
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corticosteroids in serum (Figure 5.1 A–B). Likewise, flow cytometry analysis showed 
decreased expression of the GC-inducible, anti-inflammatory protein GILZ in the myeloid 
compartment of different organs, in PBLs, and in PMs from aged animals (Data not shown and 
figure 5. C). Given the importance of macrophage activation and GC response in the aged 
immune system, we aimed to further evaluate the age-associated changes in gene expression 
and GC metabolism across tissues, as well as in the myeloid compartment of mice, to improve 
the current understanding of “macroph-aging”. 
 
 
Figure 5.1. Aged mice show a pro-inflammatory phenotype. Levels of TNF-α (A) and total corticosteroids (B) in 
serum from young (10 weeks) and aged (85 weeks) C57BL/6 mice (n=12–15), as determined by ELISA. Flow 
cytometry analysis of GILZ levels in PMs isolated from young and aged mice (C, n=8–10). Box-plots show the 
25–75
th
 percentiles (Box), mean (square), median (line) and range within 1.5 IQR (whiskers). **P<0.01, 
***P<0.001 relative to young mice.   
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5.2 Results 
5.2.1 Lipid peroxidation and clinical chemistry analysis 
To further characterise the aged-related changes of C57BL/6 mice, TBARS assay was 
performed to measure the oxidative stress levels of young and aged animals in liver tissue. 
Contrary to what could be expected, there were lower levels of malondialdehyde in livers from 
aged mice, compared with the young controls (Figure 5.2). Serum analysis of aspartate and 
alanine transaminases, triglycerides, cholesterol, albumin, and uric acid levels did not reveal 
age-related significant differences among groups (Table 5.1). 
 
 
Figure 5.2. Oxidative stress levels in livers from young and aged mice. TBARS assay was performed in liver 
tissues from young (10 weeks) and aged (85 weeks) C57BL/6 mice (n=8). MDA concentrations were normalised 
to total protein content in the sample and are presented in Box-plots showing the 25–75th percentiles (Box), mean 
(square), median (line) and range within 1.5 IQR (whiskers). **P<0.01 relative to young mice.  
Table 5.1. Clinical chemistry analysis in serum from young and aged C57BL/6 mice.  
 Female Male 
Young (n=3) Aged (n=6) Young (n=9) Aged (n=6) 
AST (U/l) 1005 (420-1450) 555 (390-800) 1015 (450-1205) 592.5 (515-890) 
ALT (U/l) 95 (50-135) 107.5 (60-190) 175 (70-425) 132.5 (75-320) 
Triglycerides (mg/dl)  105 (90-110) 82.5 (65-110) 140 (135-175) 102.5 (95-135) 
Cholesterol (mg/dl) 60 (60-65) 60 (-) 75 (65-80) 65 (60-70) 
Albumin (g/l) 35 (-) 37.5 (35-40) 30 (30-35) 35 (30-35) 
Uric acid (mg/dl) 7.5 (5-8) 8 (7-8) 7 (6-9.5) 7.5 (7-8) 
Data are presented as median (IQR). Comparison was performed with Mann Whitney U Test. No significant 
differences were detected. 
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5.2.2 Cytokine expression in tissues from aged mice 
Measurement of mRNA expression of three pro-inflammatory mediators, namely Tnf, Il1b, and 
Il6, was performed at baseline and after treatment with 5 mg/kg LPS, in different tissues from 
young and aged mice. There were no consistent differences in the expression of these mediators 
in tissue that correlated with the elevated serum cytokine levels observed by ELISA in previous 
experiments. At baseline, Tnf levels were significantly elevated in lung but decreased in lymph 
nodes of aged mice, while Il1b expression was increased in both, liver and lymph nodes (Figure 
5.3 A,C). After LPS stimulation, significant differences between groups were only found for 
Tnf expression in liver and spleen (Figure 5.3 B,D). Il6 expression was very low in all tissues, 
what impedes to draw significant conclusions from the data obtained (Appendix). 
 
5.2.3 Altered glucocorticoid homeostasis in myeloid cells from aged mice 
Further analysis focused on changes in gene expression of PMs and PBLs isolated from young 
and aged mice, given that no major differences between groups could be detected in whole 
tissues. The expression of GC-responsive genes other than GILZ was evaluated in these cells, 
finding significantly decreased levels of the dual specificity phosphatase 1 (Dusp1) gene, but 
not of Anxa1 or Sgk1 (Figure 5.4). The reduced levels of GILZ protein and Dusp1 gene 
expression might be indicative of a decreased ability of myeloid cells to respond to GC 
stimulation. Since altered regulation of genes responsible for GC homeostasis within cells could 
account for dysregulated GC-responsiveness in aging, the expression of such genes was 
investigated.  
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Figure 5.3. Expression of pro-inflammatory cytokines in tissues from young and aged mice. mRNA expression of 
Tnf and Il1b was measured in heart, liver, lung, lymph nodes, skeletal muscle, and spleen tissues from young (10 
weeks) and aged (80–100 weeks) C57BL/6 mice at baseline (A,C, n=9–13), or in liver, lung, lymph nodes, and 
spleen after treatment with 5 mg/kg LPS for 4 hours (B,D, n=4–6). mRNA expression was normalised against the 
housekeeping gene (Ppia) and is presented as fold change of young. Box-plots show the 25–75th percentiles (Box), 
mean (square), median (line) and range within 1.5 IQR (whiskers). *P<0.05, **P<0.01 relative to equally treated 
young mice. 
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Figure 5.4. Expression of GC-responsive genes in PM/PBL from young and aged mice. mRNA expression of 
Anxa1, Sgk1 and Dusp1 was measured in PMs and PBLs from young (10 weeks) and aged (80–100 weeks) 
C57BL/6 mice (n=13–14). Gene expression was normalised against the housekeeping gene (Ppia) and is presented 
as fold change of young. Box-plots show the 25–75th percentiles (Box), mean (square), median (line) and range 
within 1.5 IQR (whiskers). *P<0.05, **P<0.01 relative to young mice. 
GCs exert their action through binding to the ubiquitously expressed glucocorticoid receptor 
(GR). Therefore, changes in cellular GR expression determine GC-responsiveness (Oakley and 
Cidlowski, 2013; Ramamoorthy and Cidlowski, 2013). mRNA expression analysis, however, 
indicated that GR levels remained unchanged with aging in PMs and PBLs (Figure 5.5 A). At 
pre-receptor level, the intracellular action of GCs is largely determined by the activity of the 
two isozymes 11β-HSD1 and 11β-HSD2, that catalyse the interconversion of active 
cortisol/corticosterone and inactive cortisone/11-dehydrocorticosterone (11-DHC), thereby 
modulating GC availability (Tomlinson et al., 2004). Hsd11b1 expression was significantly 
decreased in aged mice compared with young controls, not only in PMs and PBLs, but also in 
liver, where the enzyme is most abundant (Figure 5.5 B–C). The findings at mRNA level were 
confirmed at protein level in PMs and bone-marrow derived macrophages (BMM, Figure 
5.5 D–F). Expression of the hexose-6-phosphate dehydrogenase gene (H6pd) was upregulated 
in aged PMs and PBLs. In the cell, H6PDH is the source of NADPH, needed as cofactor for 
11β-HSD1 reductase (cortisone to cortisol) activity (Atanasov et al., 2004). On the other hand, 
the gene expression of Hsd11b2, the isozyme that exerts dehydrogenase (cortisone to cortisol) 
activity, remained unchanged in PMs and PBLs from aged mice, compared with young controls 
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(Figure 5.5 G–H). These findings are indicative of alterations in intracellular GC metabolism 
in the macrophages of aged mice.  
 
 
Figure 5.5. Alterations in glucocorticoid metabolism in aged mice. Expression of GR mRNA (Nr3c1) in PMs and 
PBLs from young (10 weeks) and aged (80–100 weeks) C57BL/6 mice (n=13–14, A). Hsd11b1 expression in 
PMs, PBLs, and liver tissue from young and aged mice (B–C). 11β-HSD1 protein expression was measured in 
BMMs (D, n=4) and PMs (E, n=11–12). Representative blots are shown. Densitometric analysis, normalised to 
the housekeeping protein (α-Tubulin, E). mRNA levels of H6pd and Hsd11b2 were also measured in PMs and 
PBLs (G–H). Gene expression was normalised against the housekeeping gene (Ppia) and is presented as fold 
change of young. Box-plots show the 25–75th percentiles (Box), mean (square), median (line) and range within 
1.5 IQR (whiskers). Bars show the mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 relative to young mice. 
Chapter III 
 
74 
 
5.2.4 Reduced corticosterone levels and 11β-HSD1 activity in aged mice 
Analysis of the functional implications of reduced 11β-HSD1 expression was first performed 
by measurement of the levels of corticosterone and 11-DHC, the main GCs in rodents (Gong et 
al., 2015), in serum from young and aged mice. In line with the previous ELISA findings, aged 
mice displayed reduced levels of both corticosteroids in serum (Figure 5.6 A–B). The ratio of 
active corticosterone to inactive 11-DHC, however, remained unchanged in both groups (data 
not shown). 
 
Since 11β-HSD1 regulates the intracellular availability of active GCs, alterations in 11β-HSD1 
reductase activity were evaluated by measuring the conversion rate of deuterated cortisone to 
cortisol in isolated young and aged PMs. As could be expected, the downregulation of the 
enzyme resulted in less intracellular conversion to cortisol (Figure 5.6 C). Hence, one might 
hypothesise, in the in vivo setting reduced 11β-HSD1 expression translates into less 
corticosterone available to activate the GR in aging macrophages. 
 
 
Figure 5.6. Differences in serum glucocorticoids and 11β-HSD1 activity in young and aged mice. Serum levels 
of corticosterone and 11-DHC from young (10 weeks, n=15) and aged (80–100 weeks, n=7) male C57BL/6 mice 
were measured by LC-HRMS/MS (A,B). PMs isolated from young and aged animals (n=10) were incubated for 
24 hours with 0.1 µM and 1 µM cortisone-D8, the conversion to cortisol-D8 was measured in supernatants by LC-
HRMS/MS (C). Conversion percentages were normalised to total protein content in the sample. Box-plots show 
the 25–75th percentiles (Box), mean (square), median (line) and range within 1.5 IQR (whiskers). Bars show the 
mean ± SEM. *P<0.05, **P<0.01, relative to young mice.  
5.2.5 Upstream regulators of 11β-HSD1 are downregulated in aged macrophages 
Transcription of Hsd11b1 is regulated by members of the CCAAT/enhancer binding protein 
(C/EBP) family of transcription factors (Chapman et al., 2013). As a first insight into the 
mechanisms leading to 11β-HSD1 downregulation in aged PM and PBL, mRNA levels of 
C/EBPα and C/EBPβ were measured. Both genes were significantly downregulated in PMs 
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from aged animals. In PBLs, a similar tendency for Cebpa expression was observed, while the 
expression of Cebpb remained unchanged (Figure 5.7). 
 
 
Figure 5.7. Gene expression of upstream regulators of 11β-HSD1. Cebpa (A) and Cebpb (B) mRNA levels were 
measured in PMs and PBLs from young (10 weeks) and aged (80–100 weeks) C57BL/6 mice (n=13–14). Gene 
expression was normalised against the housekeeping gene (Ppia) and is presented as fold change of young. Box-
plots show the 25–75th percentiles (Box), mean (square), median (line) and range within 1.5 IQR (whiskers). 
**P<0.01, ***P<0.001 relative to young mice.  
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5.3 Discussion 
The aging process represents a gradual deterioration of the function and homeostasis of 
different systems that are closely linked with the onset of chronic diseases, and ultimately 
determine survival. The present work shows evaluation of the phenotype of aging C57BL/6 
mice, and reports alterations in the intracellular GC homeostasis of macrophages and PBLs 
from these mice.  
 
Oxidative stress has been signalled as a determinant factor that contributes to age-related 
inflammation (De la Fuente and Miquel, 2009). In serum (Balkan et al., 2002) and erythrocytes 
(Kawamoto et al., 2005) of aged subjects, increased levels of endogenous lipid peroxidation, 
indicative of oxidative stress, have been reported. On the other hand, the literature about lipid 
peroxidation on mammal tissues is conflicting, and the results are species-, sex-, and tissue-
dependent (Khansari et al., 2009). In this setting, age was associated with reduced hepatic lipid 
peroxidation —and thus oxidative stress— similar to previous reports in 22-month C57BL/6 
mice (Selman et al., 2008). The reduced MDA levels found in aged mice may be explained by 
conserved or improved antioxidant capacity in the liver, as previously shown for old female 
Fischer 344 rats (Rikans et al., 1991). This aspect, however, was not evaluated in the present 
study. 
 
The involvement of GC signalling and metabolism in chronic inflammation and stress-related 
disorders, two phenomena that occur with aging, has been a topic of interest for the last decades 
(Herriot et al., 2017). Literature reports indicate associations between both, higher and lower 
GC levels, and negative health outcomes (Gaffey et al., 2016; Raison and Miller, 2003). In 
rodents, increase (Kizaki et al. 2002), no differences (Morano et al., 1994) and, more recently, 
decrease (Zambrano et al., 2015) of serum corticosterone with age has been reported. Given 
that GCs have an anti-inflammatory and immunosuppressive function, it is logical to think that 
the reduced total circulating GCs, and particularly corticosterone, found in our study might 
contribute to the pro-inflammatory phenotype observed in aged mice. Nevertheless, cellular 
GC-responsiveness is ultimately determined by the intracellular availability of active GCs, as 
well as the expression of GRs. Aged PMs and PBLs, indeed, showed reduced levels of two GC-
inducible genes with important roles in the regulation of the inflammatory response: GILZ 
downregulation has been associated with increased pro-inflammatory activation of 
macrophages (Hoppstädter et al., 2015), and DUSP-1 has been shown to reduce their pro-
inflammatory cytokine expression upon LPS-activation (Abraham et al., 2006; Chen et al., 
2002).  
 
Although a previous study reported elevated GR mRNA expression in peritoneal exudate cells 
from aged mice (Kizaki et al., 1998), our findings suggest that alterations in GC-homeostasis 
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from PMs are not associated with altered GR expression but with reduced intracellular 
activation of 11-DHC by 11β-HSD1. There might be different functional implications of 
blunted 11β-HSD1 signalling in aged macrophages: it has been shown that 11β-HSD1-
defficient mice are more susceptible to endotoxemia, and macrophages derived from these mice 
are hyperresponsive to LPS stimulation (Zhang and Daynes, 2007). Loss of 11β-HSD1 in 
macrophages has also been associated with delayed phagocytic capacity (Gilmour et al., 2006). 
 
Various studies have addressed the changes in 11β-HSD1 expression and activity in different 
tissues and cell types with aging. For example, elevated expression in hippocampus from aged 
C57BL/6J mice was related to impaired cognitive function (Holmes et al., 2010). Similarly, 
protein expression was elevated in skeletal muscle from aged female volunteers, and correlated 
with reduced grip strength and insulin resistance (Hassan-Smith et al., 2015). Age-related 
elevations in 11β-HSD1 have also been reported for brown adipose tissue (Doig et al., 2017), 
skin (Tiganescu et al., 2013), and CD4+ T lymphocytes (Zhang et al., 2005). Interestingly, 11β-
HSD1 was regulated in the opposite fashion not only in PMs, but also in PBLs, a mixed 
population of granulocytes, lymphocytes, and monocytes. To our knowledge, this is the first 
report on age-induced changes in 11β-HSD1 expression in macrophages.  
 
In summary, the present data provide insight into the alterations in GC metabolism in 
macrophages during aging. The reduced circulating corticosterone levels, together with a 
decreased availability of active GC within cells as a consequence of reduced 11β-HSD1, might 
contribute to the imbalance between pro- and anti-inflammatory signalling in macrophages 
from aged mice, thus promoting the inflammaging phenotype. 
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The results presented in this chapter are part of the following manuscript, in preparation: 
 
Macroph-aging: Role of glucocorticoid metabolism 
 
J. Vanessa Valbuena Perez; Anna Dembek; Rebecca Linnenberger; Carlo Riccardi, Ph.D.; 
Stefano Bruscoli, Ph.D.; Markus R. Meyer, Ph.D.; Alexandra K. Kiemer Ph.D.; and Jessica 
Hoppstädter. Ph.D.
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Statins are essential in the pharmacotherapy for prevention of the most important cause of death 
globally, i.e. cardiovascular disease. These drugs are generally considered safe and exert a 
plethora of beneficial effects in the vasculature. SAMS, however, still represent an important 
reason for non-adherence to treatment. Because of their widespread use, even a low incidence 
in SAMS would represent a substantial number of patients affected. In the present study, GILZ 
was identified as an essential mediator of the molecular mechanisms underlying statin-induced 
muscle damage and impairment of muscle regeneration. We confirmed the importance of 
impaired protein geranylgeranylation, Akt signalling, and FoxO3 activation in statin-induced 
myotoxicity, and demonstrated that loss of GILZ can prevent statin-induced cell death.  
 
The effects of statins in muscle differentiation have been less investigated than their 
myotoxicity. This work demonstrated that GILZ induction by statins is also involved in their 
deleterious effects on myoblast differentiation, since GILZ depletion was able to partially 
rescue myogenesis in the presence of statins. Moreover, the involvement of endogenous GILZ 
in the regulation of skeletal muscle development and regeneration appears as an interesting 
topic for further research. 
 
The functional implications of GILZ induction by statins are, nonetheless, not only negative, 
since GILZ is also induced in vascular endothelial cells and macrophages, two cell types in 
which the anti-inflammatory function of this protein is well characterised. To which extent 
GILZ contributes to the pleiotropic, anti-inflammatory actions of statins, remains to be 
investigated. 
 
In conclusion, the first part of this study contributes to a better understanding of the molecular 
mechanisms underlying statin-induced myopathy, a valuable step towards the development of 
prevention strategies and safer therapy approaches for this class of drugs. Furthermore, the 
findings presented here open the opportunity to investigate the potential role of GILZ as a 
mediator of the anti-inflammatory actions of statins in the cardiovascular system. 
 
The onset of CVD and other chronic inflammatory diseases is largely predicted by age. Indeed, 
the field of geroscience considers that aging and age-related diseases share a molecular basis, 
in which inflammation plays a key role. The comprehensive investigation of the mechanisms 
that fuel, maintain, and modulate inflammaging is therefore necessary to understand its 
potential role in age-related pathogenesis and identify points for intervention. Macrophages are 
the central cell type driving the inflammatory response, and maladaptive function of aged 
macrophages largely contributes to inflammaging. The second part of this work investigated 
whether GC regulation was altered with age in this cell type, given that GCs are main 
modulators of the immune function and stress response. The data obtained provide insight into 
the alterations in GC metabolism in macrophages during aging. Reduced circulating GC levels, 
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together with a decreased availability of active GC within cells as a consequence of reduced 
11β-HSD1, might contribute to the imbalance between pro- and anti-inflammatory signalling 
in macrophages from aged mice, thus promoting the inflammaging phenotype. 
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Appendix 1  
Gene expression in tissues from young and aged WT mice. Gilz, Il6, and GR (Nr3c1) mRNA 
expression levels were measured in heart, liver, lung, lymph nodes, skeletal muscle, and spleen 
tissues from young (10 weeks) and aged (80–100) weeks C57BL/6 mice at the baseline (A,C,E, 
n=9–13), or in liver, lung, lymph nodes, and spleen after treatment with 5 mg/kg LPS for 4 
hours (B,D,F, n=4–6). Gene expression was normalised against the housekeeping gene (Ppia) 
and is presented as fold change of young. Box-plots show the 25–75th percentiles (Box), mean 
(square), median (line) and range within 1.5 IQR (whiskers). Levels below LOD in A and B 
were assigned as zero-points for illustrational purposes. **P<0.01 relative to equally treated 
young mice. 
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Gene expression in tissues from young and aged GILZ KO mice. mRNA expression was 
measured in tissues after treatment with 5 mg/kg LPS for 4 hours (n=4–6), normalised against 
the housekeeping gene (Ppia) and is presented as fold change of equally treated young WT. 
Data show mean (95% CI). *P<0.05 relative to equally treated young WT mice, as determined 
by Welch’s t-test. 
 
  
  Relative mRNA expression [x-fold] 
Tnf  Il1b Il6 Nr3c1 
Young 
KO 
Liver 2.16 (0.73-3.58) 1.27 (0.43-2.10) 0.92 (0.02-1.82) 1.72 (0.17-3.26) 
Lung 0.81 (0.38-1.24) 1.05 (0.39-1.72) 1.45 (-0.25-3.15) 
2.05  
(0.92-3.19)* 
Lymph nodes 2.24 (0.98-3.50) 1.23 (0.44-2.02) 0.88 (-0.41-2.17) 1.27 (0.15-2.39) 
Spleen 
0.63  
(0.38-0.89)* 
2.48 (0.07-4.90) 0.98 (-0.10-2.06) 0.79 (0.28-1.30) 
Aged KO 
Liver 3.51 (1.52-5.49) 1.30 (0.34-2.26) 1.49 (0.98-2.00) 11.8 (9.53-14.2) 
Lung 0.85 (0.28-1.42) 1.95 (0.39-3.51) 0.75 (-0.04-1.53) 1.22 (0.65-1.78) 
Lymph nodes 0.45 (0.27-0.63) 0.84 (0.33-1.36) 12.9 (-1.13-26.9) 1.76 (0.55-2.97) 
Spleen 0.56 (0.36-0.76) 1.60 (-0.08-3.27) 2.60 (0.36-4.83) 1.06 (0.53-1.60) 
Appendix 
 
98 
 
Appendix 2  
Gene expression in PM/PBL from young and aged WT mice. mRNA expression levels were 
measured in PMs and PBLs from young (10 weeks) and aged (80–100 weeks) C57BL/6 mice 
(n=13–14). Gene expression was normalised against the housekeeping gene (Ppia) and is 
presented as fold change of young. Box-plots show the 25–75th percentiles (Box), mean 
(square), median (line) and range within 1.5 IQR (whiskers). ***P<0.001 relative to young 
mice. 
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Gene expression in PM/PBL from young GILZ KO mice. mRNA expression levels were 
measured in PMs and PBLs from young (10 weeks) GILZ KO mice (n=11). Gene expression 
was normalised against the housekeeping gene (Ppia) and is presented as fold change of young 
WT. Data show mean (95% CI). **P<0.01, ***P<0.001 relative to young WT mice, as 
determined by Welch’s t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Gene PM PBL 
Tnf 1.26 (0.32-2.20) 0.66 (0.53-0.80) 
Mmp9 1.31 (0.89-1.73) 1.31 (1.03-1.60) 
Nr3c1 0.86 (0.73-1.00) 1.73 (1.37-2.10)** 
Anxa1 1.66 (1.28-2.04)** 3.16 (1.88-4.44)** 
Dusp1 1.38 (0.63-2.13) 1.04 (0.68-1.40) 
Sgk1 1.63 (1.19-2.07) 0.91 (0.50-1.32) 
Hsd11b1 0.62 (0.36-0.89) 0.96 (0.77-1.15) 
Hsd11b2 1.14 (0.70-1.57) 1.12 (0.78-1.46) 
H6pd 0.23 (0.18-0.28)*** 1.06 (0.64-1.47) 
Cebpa 0.85 (0.49-1.22) 1.10 (0.62-1.59) 
Cebpb 0.98 (0.70-1.26) 1.23 (0.76-1.69) 
Cdkn1a 1.02 (0.67-1.37) 1.37 (0.63-2.11) 
Cdkn2a 1.49 (0.98-2.00) 1.89 (0.92-2.87) 
Sirt1 0.96 (0.64-1.29) 0.87 (0.60-1.15) 
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Appendix 3 
Gene expression in skeletal muscle from young and aged mice. mRNA expression levels were 
measured in skeletal muscle tissue from young (10 weeks) and aged (80–100 weeks) C57BL/6 
mice (n=13–14). Gene expression was normalised against the housekeeping gene (Ppia) and is 
presented as fold change of young. Box-plots show the 25–75th percentiles (Box), mean 
(square), median (line) and range within 1.5 IQR (whiskers). 
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